
# **RESEARCH ARTICLE**



# Impact of preoperative anemia on patients undergoing total joint replacement of lower extremity: a systematic review and meta-analysis



Fu-Qiang Zhang<sup>2†</sup>, Yong-Ze Yang<sup>1,2\*†</sup>, Peng-Fei Li<sup>1,2</sup>, Guo-Rong Ma<sup>1,2</sup>, An-Ren Zhang<sup>1,2</sup>, Hui Zhang<sup>2</sup> and Hong-Zhang Guo<sup>2\*</sup>

# Abstracts

**Purpose** Preoperative anemia increases postoperative morbidity, mortality, and the risk of allogeneic transfusion. However, the incidence of preoperative anemia in patients undergoing total hip arthroplasty and total knee arthroplasty (TKA) and its relationship to postoperative outcomes has not been previously reported.

**Methods** We conducted a comprehensive literature search through PubMed, Cochrane Library, Web of Sincien, and Embase from inception to July 2023 to investigate the prevalence of preoperative anemia in patients undergoing Total Joint Arthroplasty, comorbidities between anemic and non-anemicpatients before surgery, and postoperative outcomes. postoperative outcomes were analyzed. Overall prevalence was calculated using a random-effects model, and heterogeneity between studies was examined by Cochran's Q test and quantified by the *I*<sup>2</sup> statistic. Subgroup analyses and meta-regression analyses were performed to identify sources of heterogeneity. Publication bias was assessed by funnel plots and validated by Egger's test.

**Results** A total of 21 studies with 369,101 samples were included, all of which were retrospective cohort studies. 3 studies were of high quality and 18 studies were of moderate quality. The results showed that the prevalence of preoperative anemia was 22% in patients awaiting arthroplasty; subgroup analyses revealed that the prevalence of preoperative anemia was found in the Americas; preoperative anemia was more prevalent in the female than in the male population; and preoperative anemia with a history of preoperative anemia; patients with joint replacement who had a history of preoperative anemia had an increased risk of infection, postoperative blood transfusion rate, postoperative blood transfusion, Deep vein thrombosis of the lower limbs, days in hospital, readmission within three months, and mortality compared with patients who did not have preoperative anemia.

<sup>+</sup>Fu-Qiang Zhang and Yong-Ze Yang contributed equally to this work.

\*Correspondence: Yong-Ze Yang 284091278@qq.com Hong-Zhang Guo g\_hz@163.com Full list of author information is available at the end of the article



© The Author(s) 2024, corrected publication 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. **Conclusion** The prevalence of preoperative anemia in patients awaiting total joint arthroplasty is 22%, and is higher in TKA and female patients undergoing revision, while preoperative anemia is detrimental to the patient's postoperative recovery and will increase the risk of postoperative complications, transfusion rates, days in the hospital, readmission rates, and mortality.

**Keywords** Anemia, Arthroplasty, Replacement, Knee, Arthroplasty, Replacement, Hip, Treatment outcome, Metaanalysis, Preface

# Preface

The ability to recover after arthroplasty depends on the patient's preoperative status. Preoperative hemoglobin is a functional reserve component that can be altered [1-3]. At the same time, preoperative anemia is relatively common in patients undergoing elective arthroplasty (15-30%) [4] and is associated with a poor prognosis after primary arthroplasty and revision. The World Health Organization (WHO) defines anemia as a hemoglobin (HB) concentration < 120 g/L in non-pregnant women and <130 g/L in men.Untreated preoperative anemia during surgery is associated with increased postoperative complications, mortality, length of hospital stay, and a threefold increase in the risk of requiring allogeneic blood transfusion (ABT) [5–8]. Allogeneic blood transfusion is associated with inherent risks including infection, delayed wound healing, fluid overload, and transfusionassociated lung injury (TRALI) [9]. The risk of allogeneic blood transfusion is associated with inherent risks including infection, delayed wound healing, fluid overload, and transfusion-associated lung injury (TRALI). ABT is also associated with prolonged hospitalization [10, 11], and blood products are expensive[12]. Therefore, it is important to understand and address preoperative anemia from clinical and health economics perspectives.

Currently, total lower extremity arthroplasty, including THA, TKA, revision of total hip arthroplasty (rTHA), and revision of total knee arthroplasty (rTKA), is a very popular and safe procedure for the treatment of osteoarthritis. With significant advances in surgical techniques and implant design, coupled with an increasingly aging population, the demand for lower-extremity arthroplasty continues to increase [13]. However, anemia is prevalent in older patients undergoing TJA, one study reported that 44% of patients admitted to the hospital awaiting total joint arthroplasty were anemic, with this percentage increasing to 87% postoperatively [4]. In addition, the aging population means that more patients with increasing frailty and comorbidities, such as anemia, are requiring hip and knee replacement. Increased complications and mortality after primary and revision TJA are associated with preoperative anemi [14]. Patients with severe preoperative anemia before TKA are at significant risk of postoperative DVT, sepsis, wound infection, and wound stemming [15]. Preoperative anemia has also been shown to be a risk factor for increased economic burden after TJA owing to higher transfusion rates, longer hospital stays, and transfusion-related complications [16, 17]. Patients with moderate to severe anemia are more likely to have postoperative complications than those with mild anemia, and there is a significant correlation between increased postoperative complications and the severity of anemia in patients undergoing TJA [17]. Therefore, we conducted this systematic review and meta-analysis, which is the first study to summarize the incidence of preoperative anemia and postoperative clinical outcomes in patients undergoing primary or revision total knee and hip arthroplasty.

The main aim of this systematic review and metaanalysis was to investigate the prevalence of preoperative anemia in patients awaiting total lower limb arthroplasty, and the impact of preoperative anemia on clinical outcomes following total joint arthroplasty. This study extends our understanding of the relationship between preoperative anemia and subsequent arthroplasty. We hypothesized that patients with preoperative anemia would have similar outcomes after THA or TKA compared with patients without preoperative anemia.

## **Materials and methods**

The published literature was comprehensively reviewed and reported by the Assessing Methodological Quality in Systematic Reviews (AMSTAR) [18] and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, which include requirements essential for transparent reporting of results [19]. Our research protocol was registered in (Prospero: CRD42023443351) for literature selection, eligibility criteria evaluation, data extraction, and analysis.

## Search strategy

We conducted a literature search in PubMed, Web of Science, Cochrane Library, and EMbass to analyze the prevalence of preoperative anemia in patients undergoing total hip replacement or total knee arthroplasty from inception to July 2023 and the impact on clinical outcomes. Keywords and Medical Subject Headings (MeSH)

Page 3 of 22

terms were used in the search, and the following search terms were used in various combinations: "anemia", "preoperative", "total knee arthroplasty", "total hip arthroplasty", "TKA", and "THA". To broaden the scope of the retrieval, no restrictions were set for the language, and relevant articles were found as comprehensively as possible. The search strategy for the four databases is detailed in Additional file 1: Appendix 1. Two independent authors performed all searches to identify studies related to THA or TKA. During the full-text review stage, the reviewers discussed discrepancies until a consensus was reached.

## **Eligibility criteria**

Two authors were independently screened for eligibility to participate in the study based on the title and abstract. Full articles were reviewed based on the inclusion and exclusion criteria. Any disagreements during the selection process were resolved through discussion between the two authors and another professor.

- 1. The inclusion criteria are as follows:
- (1) Cross-sectional or longitudinal observational study.
- (2) at least one finding was reported in this study.
- (3) The comparisons listed should include patients with preoperative anemic and preoperative non-anemic.
- (4) Articles identified in any language type.
- (5) Full-text articles can be accessed.
- 2. Exclusion criteria such as:
- (1) Reviews, conference abstracts, case reports, letters to the editor, journal articles, or commentaries.
- (2) Studies that were unavailable in full or did not provide sufficient data on the prevalence of anemia.
- (3) It was not possible to extract raw data from the comparison results.

## **Data extraction**

Before the start of the study, two reviewers independently extracted and recorded the extracted data in a collaborative online spreadsheet (Excel sheet). A third reviewer repeated the data extraction and compared the results for validation. The reviewer recorded the first author, year of publication, study design, sample size, type of surgery, characteristic sample (including age, number of males and females, and MBI), and article type. Outcomes included the prevalence of preoperative anemia and its relation to perioperative blood transfusion, number of postoperative blood transfusions, preoperative comorbidities involving a history of hypertension (HTN), diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD), preoperative comorbidities including DVT, infections (superficial and deep), and in-hospital mortality.T1DM, T2DM, and other secondary DM (e.g., insulin-dependent DM and non-insulin-dependent DM) were not analyzed separately; all subgroups were categorized as DM groups in our study. In studies where metaanalysis data were missing or unavailable, or data were presented only graphically, attempts were made to contact the corresponding authors by email. If necessary, the need for extraction of incomplete data was waived, and when disagreements arose during data collection, they were resolved by discussion.

## **Quality assessment**

The literature search did not yield randomized studies. The Newcastle–Ottawa Scale (NOS) was used to assess the methodological quality of non-randomized case– control studies [20] which consists of eight items with a total score of 9. "Good" was defined as a total score of 7–9, "Fair" as a score of 4–6, and "Poor" as a score of less than 4. All the selected articles were independently reviewed by two authors for quality assessment. Disagreements were resolved by discussion. Kappa scores for the inter-reviewer agreement were as follows: <0.2 normal, 0.40–0.59; good, 0.60–0.74; and very good,  $\geq$ 0.75.

## **Quality of evidence**

The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was used to assess the quality of evidence for outcomes [21]. Evidence may be reduced by five factors: study limitations, inconsistency, indirectness, imprecision, and publication bias; factors that may improve the quality of evidence from observational studies: large effect sizes, negative bias, and dose–effect relationships. The results of studies with moderate or large effect sizes may lead to an improved quality of evidence. Four quality levels were used: high, moderate, low, and very low quality.

## Statistical analyses

We used R software (4.3) to determine pooled prevalence and performed a meta-analysis of preoperative anemia in patients awaiting hip or knee replacement. Given the high degree of heterogeneity expected in observational studies, we used a random-effects model to calculate the pooled estimates. To stabilize the variance, the study data were transformed using the Freeman-Tukey doubleorthogonal string transformation. We analyzed heterogeneity using Cochran's Q test, and the  $I^2$  statistic with a threshold of  $I^2 \ge 50\%$  heterogeneity was considered high.

We conducted a subgroup analysis of the factors that may influence the prevalence of preoperative anemia in total joint arthroplasty to explore the sources of heterogeneity, namely gender, type of surgery, and continent; this is due to differences in gender, as females have lower hemoglobin levels than males, and changes in the physiological cycle of females make females more susceptible to anemia; and the causes of preoperative anemia are more complex in revision joints compared with firsttime total joint arthroplasty. The causes of preoperative anemia in revision arthroplasty are more complex, and may be related to the combination of long-term chronic infection and inflammation; in addition, the incidence of anemia varies in different regions due to the differences in economic level, medical level, the standard of living, and dietary habits of different regions, and therefore, the incidence of anemia is different in different regions according to gender, type of surgery (THA, TKA, rTHA, rTKA), and continent (Europe, Asia, and America), Asia, America) on anemia was analyzed in subgroups. When meta-analyzing preoperative anemia subgroups, preoperative comorbidities, and postoperative clinical outcomes, dichotomous outcomes or continuous outcomes were assessed using relative risk (RR) with 95% confidence intervals (CI) or standardized mean differences (MD) with 95% confidence regions, respectively. A significance level of P < 0.05 was used, and  $I^2$  was used to evaluate heterogeneity. If  $I^2 < 50\%$ , a fixed-effects model was used because of low heterogeneity.  $I^2 \ge 50\%$  was considered significant heterogeneity, and a random-effects model was used to calculate pooled estimates. Sensitivity analyses were performed by sequentially deleting studies to determine the source of heterogeneity [22]. Publication bias was assessed by visual inspection of funnel plots and Egger's test [23].

# Results

## Literature search and characteristics

Figure 1 summarizes the search and selection process. An electronic search yielded 565 citations from the database. A total of 298 citations were removed because of duplication, and 216 citations were excluded by title and abstract screening. A total of 51 articles were selected for full-text screening. Nine were read in full text to exclude inappropriate literature, 8 had no comparable information between the preoperative anemic and non-anemic groups, 10 had incomplete or unavailable data, and 13 were unavailable in full text. Finally, this study ultimately included 21 studies published between 2003 and 2019 studies were included in the qualitative and quantitative synthesis.The total number of patients included in this meta-analysis was 369,101, of whom 162,480 were women and 206,621 were men. The number of patients in each study ranged from 154 to 293,043. Studies were conducted on four continents and in 10 countries: the United Kingdom [24–29], China [30], Denmark [1], United States [14, 17, 31, 32], Singapore [7, 33], France [34], Australia [35], Germany [36, 37], Canada [38] and Brazil [39]. The mean age range for inclusion in the studies was  $63.1 \pm 11.7$  years to  $74.06 \pm 1.5$  years. A total of 369,101 patients who underwent total joint arthroplasty were enrolled, including 56,175 patients with preoperative anemia and 312,926 patients without preoperative anemia. 21 Twenty-one studies had confirmed articles describing patients treated with primary THA or TKA. Specifically, nine studies [1, 17, 26, 29, 31, 32, 34, 38, 40] investigated TKA, 9 studies [1, 17, 28, 30-32, 34, 38, 40] investigated THA, and 5 studies [14, 24, 31, 32, 40] investigated rTKA and rTHA. Detailed characteristics of each study are presented in Table 1.

## Methodological quality

The overall Kappa score for the consistency of methodological quality assessment between the two evaluators was 0.905 (Additional file 3: Annex 3). The quality scores ranged from 4 to 7 (maximum: 9), with a mean score of 5.6. There were 18 'fair' studies [1, 7, 14, 25, 26, 31, 33–36, 38, 39], and 3 'good' studies [17, 24, 32]. The NOS scores for methodological quality for each study are presented in Table 2.

1. Prevalence of anemia before waiting for total joint arthroplasty

In 21 studies, with a total of 369,101 individuals, the prevalence of combined preoperative anemia in patients undergoing total joint arthroplasty was 22% (95% CI 17–27%;  $I^2$ =100%; P<0.01) (Fig. 2). To explore the sources of heterogeneity, subgroup analyses were performed according to sex, type of surgery, and continent.

2. Analysis of incidence rates by subgroup

## (1) Type of surgery

Nine studies [1, 17, 26, 29, 31, 32, 34, 38, 40] investigated the prevalence of preoperative anemia in THA, nine studies investigated TKA[1, 17, 28, 30–32, 34, 38, 40] investigated the prevalence of preoperative anemia in TKA, five studies[14, 24, 31, 32, 40] investigated the prevalence of preoperative anemia in rTHA, and five studies[14, 24, 31, 32, 40] investigated the prevalence of preoperative anemia in rTKA. The overall prevalence




Fig. 1 Preferred reporting items of systematic reviews and met-analysis (PRISMA) flow diagram

of preoperative anemia in patients with THA, TKA, rTHA, and rTKA combined was 15.2% (95% CI 15.2–17.5%;  $I^2 = 95$  0.3%; P < 0.01), 18.2% (95% CI 13.9–22.4%;  $I^2 = 98.54$ %; P < 0.01), 35.7% (95% CI 13.9–22.4%; P < 0.01), 35.7% (95% CI 13.4%;  $I^2 = 98.54$ %; P < 0.01), 35.7% (95% CI 26.8–44.6%;  $I^2 = 98.84$ %; P < 0.01) and 38.3% (95% CI 29.3–47.2%;  $I^2 = 97.5$ %; P < 0.01) (Fig. 3).

## (2) Different continents

When we analyzed the prevalence of preoperative anemia according to different continents, significant differences were observed. In Europe [1, 24–29, 34, 36, 37, 40],the prevalence was 16.9%,(95% CI 13.0–21.1%;  $I^2 = 99.0\%$ ; P < 0.01); in Asia [7, 30, 33],–the prevalence in

Table 1 Chai	Characteristics of the included studies	he included st	udies								
Author(s) (etc.) Year	Nations	Type of study	research period	Type of surgery	sample size	Number of men/women	Age (mean (SD); Range (years)	BMI (kg/m²)	Anaemia criteria	Number of preoperative anemia	Outcome
Sandean et al. [28]	United King- dom	A retrospec- tive study	2009–2017	ТНА	THA:1095	unspecified	72	unspecified	< 130 g/L for men or < 115 g/L for women	192	_
Xiong et al. [30]	China	A retrospec- tive study	2017–2021	ТКА	TKA:1005	208/797	Anaemic group: 69.87 ± 8.60 Non-anaemic group: 69.87 ± 8.60	Anaemia group: 24.87 ± 3.57 Non-anaemic group 25.81 ± 2.46	Hb < 130 g/L for men or < 120 g/L for women	342	1, 2, 8, 9
Sandean et al. [29]	United King- dom	A retrospec- tive study	2016–2018	ТКА	ТКА:2296	883/1413	72	unspecified	< 130 g/L for men or < 115 g/L for women	350	
Saleh et al. [27]	United King- dom	A retrospec- tive study	2000-2001	ТНА/ТКА	ТНА:621 ТКА:521	unspecified	68	unspecified	< 130 g/L for men or < 115 g/L for women	210	
Lasocki et al. [34]	French	A retrospec- tive study	2010-2011	ТНА/ТКА	THA:765 TKA:570	397/938	64±12.3	unspecified	Hb < 130 g/L for men and < 120 g/L for women	217	1, 7, 10
Myers et al. [25]	United King- dom	A retrospec- tive study	1999–2000	ТНА	THA:225	137/88	Anaemic group: 62 Non-anaemic group: 64	unspecified	< 130 g/L for men or < 115 g/L for women	35	1, 2, 13
Jans et al. [1]	Denmark	A retrospec- tive study	2010-2011	ТНА/ТКА	ТНА:2702 ТКА:2463	2229/2936	67±11	unspecified	Hb < 130 g/L for men and < 120 g/L for women	662	1, 2, 3, 4, 7, 8, 10, 11
Lu et al. [14]	United States of America	A retrospec- tive study	2006–2014	гТНА/гТКА	rTHA:3871 rTKA:2959	3814/3016	Anaemia group: 68.1 ± 12.1 Non-anaemic group:67.9±11.4	Anaemia group: 31±7 Non-anaemic group: 30.9±8	Hb < 130 g/L for men and < 120 g/L for women	3415	1, 2, 3, 4, 5, 6, 8, 9, 10, 11
Lu et al. [14]	United States of America	A retrospec- tive study	2006–2014	rTHA/rTKA	rТНА:1107 rTKA:1543	1364/1286	Anaemia group: 64.3 ± 11.7 Non-anaemic group:66.3 ± 12	Anaemia group: 31.9±7.6 Non-anaemic group 31.6±8	Hb < 130 g/L for men and < 120 g/L for women	1325	1, 2, 3, 4, 5, 6, 8, 9, 10, 11

Table 1 (continued)	tinued)										
Author(s) (etc.) Year	Nations	Type of study	research period	Type of surgery	sample size	Number of men/women	Age (mean (SD); BMI (kg/m <sup>2</sup> ) Range (years)	BMI (kg/m²)	Anaemia criteria	Number of preoperative anemia	Outcome
Kasivisvana- than et al. [24]	United King- dom	A retrospec- tive study	2004–2014	rTHA/rTKA	rTHA:3021 rTKA:2366	2409/2978	70.1 ± 8.4	unspecified	Hb < 130 g/L for men and < 120 g/L for women	1956	1, 2, 3, 4, 8, 10, 12
Abdullah et al. [7]	Singaporean	A retrospec- tive study	2013–2014	TKA	TKA:2394	579/1815	65.9±8.0	unspecified	Hb < 130 g/L for men and < 120 g/L for women	567	-
Evans et al. [35]	Australia	A retrospec- tive study	2009.1– 2009.7	TJA	TJA:154	69/85	66.35	unspecified	Hb < 130 g/L for men and < 120 g/L for women	15	1, 8, 13
Wan et al. [40]	Sweden	A retrospec- tive study	2016–2018	THA/TKA/ rTHA/rTKA	881	533/348	Anaemia group: 69.5 Non-anaemic group: 65.2	unspecified	Hb < 130 g/L for men and < 120 g/L for women	189	1, 5, 8, 10, 12
Gu et al. [17]	United States of America	A retrospec- tive study	2012-2017	ТНА	THA:108 b,966	THA:108 b,966 48,743/60223	Anaemic group: 64.63 ± 10.715 Non-anaemic group: 68.01 ± 11.49	Anaemia group: 29.9 ±6.53 Non-anaemic group 30.5 ±6.35	Hb<130 g/L for men and<120 g/L for women	14,751	1, 2, 3, 4, 6, 8, 9, 11, 12
Gu et al. [17]	United States of America	A retrospec- tive study	2012-2017	ТКА	ТКА:184,077	69,415/114662	Anaemic group: 66.34±9.34 Non- anaemic group: 68.80±9.84	Anaemia group: 32.6 ± 7.16 Non-anaemic group 33.2 ± 6.84	Hb < 130 g/L for men and < 120 g/L for women	23,637	1, 2, 3, 4, 6, 8, 9, 11, 12
Greenky [31]	United States of America	A retrospec- tive study	2000-2007	ТНА/ТКА/ гТНА/гТКА	THA: 7230 TKA: 6371 rTHA: 1121 rTKA: 500	6494/8727	Anaemic group: 65.92 ± 12.9 Non- anaemic group: 63.14 ± 12.2	Anaemic group: 29.7 ± 8.32 Non-anaemic group 30.27 ± 10.7	Hb < 130 g/L for men and < 120 g/L for women	1991	1, 2, 3, 4, 5, 9, 10, 12
Rogers et al. [26]	United King- dom	A retrospec- tive study	unspecified	ТНА	THA:322	141/181	67	unspecified	Male and female Hb ≤ 120 g/L	26	
Duarte et al. [39]	Brazilian	A retrospec- tive study	2017-2020	ALT	TJA:234	99/134	Anaemic group: 74.06±1.59 Non- anaemic group: 68.84±1.29	unspecified	Hb < 130 g/L for men and < 120 g/L for women	72	1, 7, 8, 10, 11, 12

Zhang et al. Journal of Orthopaedic Surgery and Research (2024) 19:249

Page 7 of 22

Table 1 (continued)	ntinued)										
Author(s) (etc.) Year	Nations	Type of study	research period	Type of surgery	sample size	Number of men/women	Age (mean (SD); Range (years)	BMI (kg/m²)	Anaemia criteria	Number of preoperative anemia	Outcome
Schatz et al. [37]	German	A retrospec- tive study	2019-2020	TKA	TKA:341	147/126	71.3±9.0	Anaemia group: 26.7±4.6 Non-anaemic group 28.4±4.6	Hb < 130 g/L for men and < 120 g/L for women	42	
Abdullah et al. [33]	Singaporean	A retrospec- tive study	2013–2014	ТКА	TKA:1994	473/1521	67.3	unspecified	Hb < 130 g/L for men and < 120 g/L for women	445	1, 3, 8,
Bailey et al. [38]	Canadian	A retrospec- tive study	2016–2017	ТНА/ТКА	ТНА:2283 ТКА:2457	2417/2967	Anaemic group: 70.4±11.4 Non-anaemic group: 63.7±11.7	Anaemia group: $30.6\pm6.7$ Non-anaemic group $31.1\pm7.0$	Hb<130 g/L for men and<120 g/L for women	817	1, 5, 6, 8, 11
Viola et al. [32]	Viola et al. [32] United States of America	A retrospec- tive study	2000–2013	ТНА/ТКА/ rTHA/rTKA	ТНА: 6320 ТКА: 5619 rTHA: 1012 rTKA: 612	5962/7601	Anaemia group: 66.1±12.4 Non-anaemic group: 63.1±11.7	Anaemic group: 29.9±6.9 Non-anaemic group: 30.3±6.4	Hb<130 g/L for men and<120 g/L for women	2576	1, 8, 10, 12
Meybohm et al. [36]	German	A retrospec- tive study	2017–2018	ТНА/ТКА	THA:4813 TKA:3162	3382/4593	70	unspecified	Hb < 130 g/L for men and < 120 g/L for women	1372	1, 10, 12
1, prevalence ο 5, postoperativ 3 months; 12, π TJA total joint ar	1, prevalence of preoperative anemia in total joint 5, postoperative deep infections; 6, postoperative : 3 months; 12, mortality rate, 13 causes of anaemia TJA total joint arthroplasty, THA total hip arthroplas	nia in total joint al , postoperative su 	rthroplasty; 2, pre uperficial infectior <i>i</i> , <i>TKA</i> , total knee a	operative combir s; 7, blood transfi arthroplasty, <i>rTHA</i>	ned hypertension; fusion; 8, transfusio A revision of total hi	3, preoperative con on rate; 9, deep vein ip arthroplasty, <i>rTK</i> /	<ol> <li>prevalence of preoperative anemia in total joint arthroplasty; 2, preoperative combined hypertension; 3, preoperative combined diabetes mellitus; 4, preoperative combined chronic obstructive pulmonary disease;</li> <li>postoperative deep infections; 6, postoperative superficial infections; 7, blood transfusion; 8, transfusion rate; 9, deep vein thrombosis in the lower limbs; 10, number of days in hospital; 11, rehospitalisation rate in 3 months; 12, mortality rate, 13 causes of anaemia</li> <li>TA total joint arthroplasty, THA total hip arthroplasty, TKA revision of total hip arthroplasty, rTKA revision of total knee arthroplasty, IR infection-free refurbishment, IR infection refurbishment</li> </ol>	us; 4, preoperative er limbs; 10, numk arthroplasty, <i>IFR</i> ir	e combined chron oer of days in hos nfection-free refur	c obstructive puln bital; 11, rehospital bishment, <i>IR</i> infec	isation rate in tion refurbishment

Zhang et al. Journal of Orthopaedic Surgery and Research (2024) 19:249

Inclusion in the study	Sele	ction of re	esearch su	ıbjects	Comparability	Outco	ome measu	rement	Rating	GRADE
	1	2	3	4		A	В	С		
Sandean et al. [28]	_	*	*	-	*	*	-	_	4	Fair
Xiong et al. [30]	*	*	*	-	*	*	-	*	5	Fair
Sandean et al. [29]	*	*	*	-	*	*	-	×	6	Fair
Saleh et al. [27]	*	*	*	-	*	*	-	-	5	Fair
Lasocki et al. [34]	*	*	*	-	*	*	-	*	6	Fair
Myers et al. [25]	*	*	*	-	*	*	-	*	6	Fair
Jans et al. [1]	*	*	*	-	*	*	-	*	5	Fair
Lu et al. [14]	-		*	-	*	*	*	*	5	Fair
Kasivisvanathan et al. [24]	*	*	*	-	*	*	*	*	7	Good
Abdullah et al. [7]	*	*	*	-	*	*	-	-	5	Fair
Evans et al. [35]	*	*	*	-	*	*	-	-	5	Fair
Wan et al. [40]	*		*	-	*	*	-	*	4	Fair
Gu et al. [17]	*	*	*	-	*	*	*	*	7	Good
Greenky [31]	*	*	*	-	×	*	-	-	6	Fair
Rogers et al. [26]	*	*	*	-	×	*	-	-	5	Fair
Duarte et al. [39]	*	*	*	-	*	*	-	*	6	Fair
Schatz et al. [37]	*	*	*	-	**	*	-	*	6	Fair
Abdullah et al. [33]	*	*	*	-	×	*	-	-	5	Fair
Bailey et al. [38]	*	*	*	-	*	*	-	*	6	Fair
Viola et al. [32]	*	*	*	-	*	*	*	*	7	Good
Meybohm et al. [36]	*	*	*	-	*	*	-	*	6	Fair

 Table 2
 Quality evaluation results of non-randomised controlled studies

1. Representativeness of the exposure cohort; 2. Selection of unexposed; 3. Determination of exposure; 4. Outcomes not present at the start; A. Outcome B. Adequate follow-up time; C. Adequacy of follow-up

Asia was 26.5%, (95% CI 19.7–33.8%;  $I^2 = 96\%$ ; P < 0.01); in the Americas, the prevalence was 28.5% [14, 17, 31, 32, 38, 39]. (95% CI 16.1–42.9%;  $I^2 = 100$ ; P = 0.01) (Fig. 4).

## (3) Gender differences

When we analyzed the prevalence of preoperative anemia according to sex, in males the prevalence was 22.8% [1, 14, 17, 24–26, 30–33, 37–40]. The prevalence of preoperative anemia was 22.8%, (95% CI 16.0–30.4%;  $I^2$ =100%; P<0.01) in males and 25.5%, (95% CI 19.5–32.1%;  $I^2$ =100%; P<0.01) in females [1, 14, 17, 24–26, 30–33, 37–40]. The prevalence was 25.5%, (95% CI 19.5–32.1%;  $I^2$ =100%; P<0.01) (Fig. 5).

## 3. Preoperative comorbidities

## (1) Combined hypertension

Seven studies [1, 14, 17, 24, 25, 30, 31] reported preoperative anemic or non-anemic patients with preoperative comorbid hypertension. A random-effects model found a higher prevalence of hypertension in patients with preoperative anemia (RR=1.26, 95% CI [1.04,1.53], P < 0.00001,  $I^2 = 100\%$ ) (Fig. 6); however, this finding may be influenced by high heterogeneity (The results of sensitivity analysis are shown in Additional file 4: Annex 4).

#### (2) Combined diabetes mellitus

Six studies [1, 14, 17, 24, 31, 33] reported preoperative anemic patients or preoperative non-anemic patients with preoperative comorbid diabetes, random-effects models suggested that preoperative anemia increased the risk of diabetic disease (RR = 1.59, 95%CI [1.36,1.86] P < 0.01,  $I^2 = 96\%$ ) (Fig. 7). However, this finding may have been affected by high heterogeneity (The results of sensitivity analysis are shown in Additional file 4: Annex 4).

(3)Combined chronic obstructive pulmonary disease (COPD)

Five studies [1, 14, 17, 24, 31] investigated the incidence of preoperative anemic or preoperative non-anemic in patients with preoperative COPD comorbidities. A random-effects model revealed a difference in the increased incidence of COPD in patients with preoperative anemia

Study	Events	Total			Proportion	95%-CI	Weight (common)	Weight (random)
Sandean 2021	192	1095			0.18	[0.15; 0.20]	0.2%	4.6%
Xiong 2023	342	1005			0.34	[0.31; 0.37]	0.1%	4.5%
Sandean 2020	350	2296	<del>'+-</del>		0.15	[0.14; 0.17]	0.6%	4.6%
Saleh 2007	224	1142			0.20	[0.17; 0.22]	0.2%	4.6%
Lasocki 2015	174	1335	-+ <u>+</u>		0.13	[0.11; 0.15]	0.4%	4.6%
Myers 2004	35	225			0.16	[0.11; 0.21]	0.1%	4.4%
Jans 2014	662	5165	+		0.13	[0.12; 0.14]	1.5%	4.6%
Lu 2017(IFR )	3415	6830		+	0.50	[0.49; 0.51]	0.9%	4.6%
Lu 2017(IR)	1325	2650				[0.48; 0.52]	0.3%	4.6%
Kasivisvanathan 2016	1956	5387	+	-	0.36	[0.35; 0.38]	0.8%	4.6%
Abdullah 2017	567	2394	-			[0.22; 0.25]	0.4%	4.6%
Evans 2011	15	154				[0.06; 0.16]	0.1%	4.4%
Wan 2020	189	881			0.21	[0.19; 0.24]	0.2%	4.5%
Gu 2020	38388	293043	•		0.13	[0.13; 0.13]	84.1%	4.6%
Greenky 2012	2991	15722	+		0.19	[0.18; 0.20]	3.3%	4.6%
Rogers 2008	26	322			0.08	[0.05; 0.12]	0.1%	4.5%
Duarte 2021	72	234	; — <del>— — —</del>		0.31	[0.25; 0.37]	0.0%	4.3%
Schatz 2023	42	341			0.12	[0.09; 0.16]	0.1%	4.5%
Abdullah 2019	445	1994			0.22	[0.21; 0.24]	0.4%	4.6%
Bailey 2021	817	5384	<del> +</del>		0.15	[0.14; 0.16]	1.4%	4.6%
Meybohm 2020	1372	7939	+		0.17	[0.16; 0.18]	1.8%	4.6%
Viola 2015	2576	13563	+		0.19	[0.18; 0.20]	2.9%	4.6%
Common effect model		369101			0.14	[0.14; 0.14]	100.0%	
Random effects mode	I				0.22	[0.17; 0.27]		100.0%
Heterogeneity: $I^2 = 100\%$ ,	$\tau^2 = 0.013$	6, $p = 0$						
		-	0.1 0.2 0.3	0.4 0.5				

Fig. 2 Prevalence of preoperative anaemia in total joint replacement patients

 $(RR = 1.12, 95\% CI [1.01, 1.43], P < 0.01, I^2 = 93\%)$  (Fig. 8) (The results of sensitivity analysis are shown in Additional file 4: Annex 4).

4. Postoperative clinical outcomes

# (1) Deep postoperative infections

Four studies[14, 31, 38, 40] reported the effect of preoperative anemia on deep infection after primary lowerlimb arthroplasty. Using a random-effects model, we observed an increased risk of deep infection in patients with preoperative anemia (RR=1.67, 95% CI [1.33,2.09], P < 0.081,  $l^2 = 53\%$ ) (Fig. 9).

## (2) Postoperative superficial infection

Three studies [14, 17, 24]referred to the association between preoperative anemia and superficial infections and, using a random-effects model, suggested that preoperative anemia would increase the incidence of superficial infections (RR=1.36, 95% CI [1.01, 1.84],  $P < 0.05, I^2 = 59\%$ ) (Fig. 10).

(3) Post-operative blood transfusion rate.

Eleven studies [1, 14, 17, 24, 30, 32, 33, 35, 38–40] reported a particularly significant difference in postoperative transfusion rates between preoperatively anemic and non-anemic patients (RR=3.23, 95% CI [1.91,5.47], P < 0.00001,  $I^2 = 100\%$ ) (Fig. 11) (The results of sensitivity analysis are shown in Additional file 4: Annex 4).

(4) Postoperative blood transfusion.

Three studies [1, 34, 39] mentioned the relationship between preoperative anemia and blood transfusion, using a random-effects model, suggested that preoperative anemia would increase the amount of blood transfused in postoperative patients (MD = -0.04, 95% CI [-0.27,0.20], P > 0.05,  $I^2 = 82\%$ ) (Fig. 12). However, the number of inclusions and heterogeneity  $I^2$  were large, and this result should be viewed carefully.

Study	Events	Total			Proportion	95%-CI	Weight (common)	Weight (random)
Endpoint = THA Sandean 2021 Lasocki 2015 Jans 2014 Wan 2020 Gu 2020 Greenky 2012 Rogers 2008 Bailey 2021 Viola 2015 Common effect model Random effects model Heterogeneity: $I^2 = 95\%$ ,		7230 322 - 2283 6320 130114			0.13 0.13 0.22 0.14 0.18 0.08 0.16 0.17 0.14	[0.15; 0.20] [0.11; 0.16] [0.12; 0.14] [0.18; 0.26] [0.13; 0.14] [0.17; 0.19] [0.05; 0.12] [0.15; 0.18] [0.16; 0.18] [0.14; 0.14] [0.13; 0.18]	0.3% 0.2% 0.8% 0.1% 31.5% 1.7% 0.1% 0.6% 1.5% 36.8%	3.4% 3.4% 3.3% 3.4% 3.4% 3.4% 3.4% 3.4%
Endpoint = TKA Xiong 2023 Sandean 2020 Lasocki 2015 Jans 2014 Wan 2020 Gu 2020 Greenky 2012 Bailey 2021 Viola 2015 Common effects model Random effects model Heterogeneity: $I^2 = 99\%$ ,		6371 2457 5619 205195	<pre></pre>		0.15 0.13 0.20 0.13 0.20 0.13 0.20 0.18 0.19 0.13	[0.31; 0.37] [0.14; 0.17] [0.10; 0.16] [0.11; 0.14] [0.16; 0.25] [0.13; 0.13] [0.19; 0.21] [0.16; 0.20] [0.18; 0.20] [0.13; 0.13] [0.14; 0.22]	0.2% 0.6% 0.2% 0.8% 0.1% 55.6% 1.4% 0.6% 1.3% 60.6%	3.4% 3.4% 3.4% 3.3% 3.4% 3.4% 3.4% 3.4%
Endpoint = rTHA Lu 2017 (IFR) Lu 2017 (IF) Kasivisvanathan 2016 Wan 2020 Greenky 2012 Viola 2015 Common effect model Random effects model Heterogeneity: $I^2 = 99\%$ ,		3871 1107 3021 77 1121 1012 <b>10209</b> p < 0.01		+ + + + + + + + + + + + + + + + +	0.49 0.32 0.25 0.28 0.28 0.28	[0.49; 0.52] [0.46; 0.52] [0.31; 0.34] [0.16; 0.36] [0.26; 0.31] [0.26; 0.31] [0.38; 0.40] [0.27; 0.45]	0.5% 0.1% 0.5% 0.0% 0.2% 0.2% 1.5%	3.4% 3.4% 3.0% 3.4% 3.4%  19.8%
Endpoint = rTKA Lu 2017 (IFR) Lu 2017 (IF) Kasivisvanathan 2016 Wan 2020 Greenky 2012 Viola 2015 Common effect model Random effects model Heterogeneity: $l^2 = 97\%$ ,		2959 1543 2366 36 500 612 <b>8016</b> p < 0.01		+ + + + + + + +	0.51 0.42 0.25 0.28 0.30 0.44	[0.48; 0.51] [0.48; 0.53] [0.40; 0.44] [0.12; 0.42] [0.24; 0.32] [0.26; 0.34] [0.43; 0.45] [0.29; 0.47]	0.4% 0.2% 0.3% 0.0% 0.1% 0.1% 1.1%	3.4% 3.4% 3.4% 2.6% 3.3% 3.3%  <b>19.4%</b>
Common effect model Random effects mode Heterogeneity: $l^2 = 100\%$	1	353534	0.1 0.2	0.3 0.4 0.5		[0.14; 0.14] [0.20; 0.29]	100.0% 	 100.0%
neterogeneity. / - 100%	, , = 0.0158	p, p = 0	2	0.0 0.4 0.0				

Heterogeneity:  $l^2 = 100\%$ ,  $\tau^2 = 0.0159$ , p = 0 0.1 0.2 0.3 0.4 0.5 Test for subgroup differences (common effect):  $\chi_3^2 = 5914.95$ , df = 3 (p = 0) Test for subgroup differences (random effects):  $\chi_3^2 = 40.44$ , df = 3 (p < 0.01)

Fig. 3 Prevalence of preoperative anaemia for different types of surgery

Endpoint = Europe       0.18 [0.15; 0.20]       0.2%       4.8%         Sandean 2020       350       2296       0.15 [0.14; 0.17]       0.6%       4.8%         Sandean 2020       350       2296       0.2%       4.8%         Lasocki 2015       174       1335       0.2%       4.8%         Myers 2004       35       225       0.16 [0.11; 0.2]       0.2%       4.8%         Massivanathan 2016       1956       5387       0.13 [0.12; 0.14]       1.5%       4.8%         Wan 2020       189       881       0.21 [0.19; 0.24]       0.2%       4.7%         Rogers 2008       26       322       0.08 [0.05; 0.12]       0.1%       4.7%         Meybohm 2020       1372       7939       0.17 [0.16; 0.18]       1.8%       4.8%         Common effect model       26128       0       0.18 [0.18; 0.13]       6.0%          Random effects model       5393       0.24 [0.22; 0.25]       0.4%       4.8%         Abdullah 2017       567       2394       0.24 [0.22; 0.25]       0.4%       4.8%         Abdullah 2017       567       2394       0.24 [0.22; 0.25]       0.4%       4.8%         Lu 2017(IFR)       3415       6830
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
Sandean 2020 350 2296 + 0.15 [0.14; 0.17] 0.6% 4.8% Saleh 2007 224 1142 0.20 [0.17; 0.22] 0.2% 4.8% Lasocki 2015 174 1335 + 0.13 [0.11; 0.15] 0.4% 4.8% Myers 2004 35 225 0.13 [0.11; 0.21] 0.1% 4.6% Jans 2014 662 5165 + 0.13 [0.12; 0.14] 1.5% 4.8% Wan 2020 189 881 - 0.21 [0.19; 0.24] 0.2% 4.7% Rogers 2008 26 322 - 0.08 [0.05; 0.12] 0.1% 4.7% Schatz 2023 42 341 - 0.12 [0.09; 0.16] 0.1% 4.7% Meybohm 2020 1372 7939 + 0.17 [0.16; 0.18] 1.8% 4.8% Common effect model 26128 0.17 [0.16; 0.18] 1.8% 4.8% Common effect model 26128 0.17 [0.13; 0.22] 52.3% Heterogeneity: $l^2 = 99\%$ , $t^2 = 0.0054$ , $p < 0.01$ Endpoint = Asia Xiong 2023 342 1005 - 0.17 [0.13; 0.22] 52.3% Heterogeneity: $l^2 = 99\%$ , $t^2 = 0.0034$ , $p < 0.01$ Endpoint = Asia Xiong 2023 342 1005 - 0.27 [0.19; 0.34] 14.3% Abdullah 2017 567 2394 - 0.22 [0.21; 0.24] 0.4% 4.8% Common effect model 5393 $\diamond$ 0.25 [0.24; 0.26] 1.0% Random effects model Heterogeneity: $l^2 = 96\%$ , $t^2 = 0.0039$ , $p < 0.01$ Endpoint = America Lu 2017(IFR ) 3415 6830 + 0.27 [0.49; 0.51] 0.9% 4.8% Gu 2020 38388 293043 - 0.31 [0.13; 0.13] 84.2% 4.8% Greenky 2012 2991 15722 + 0.31 [0.25; 0.37] 0.0% 4.5%
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
Lasocki 2015 174 1335 + 0.13 $[0.11; 0.15]$ 0.4% 4.8% Myers 2004 35 225 + 0.13 $[0.11; 0.21]$ 0.1% 4.6% Jans 2014 662 5165 + 0.38 $[0.35; 0.38]$ 0.8% 4.8% Wan 2020 189 881 + 0.21 $[0.19; 0.24]$ 0.2% 4.7% Rogers 2008 26 322 + 0.08 $[0.05; 0.12]$ 0.1% 4.7% Schatz 2023 42 341 + 0.12 $[0.09; 0.16]$ 0.1% 4.7% Meybohm 2020 1372 7939 + 0.77 $[0.16]$ 0.18 $[0.18]$ 0.8% 4.8% Common effect model 26128 $\diamond$ 0.18 $[0.18; 0.18]$ 6.0% Random effects model Heterogeneity: $l^2 = 99\%$ , $\tau^2 = 0.0054$ , $p < 0.01$ Endpoint = Asia Xiong 2023 342 1005 + 0.22 $[0.21; 0.24]$ 0.4% 4.8% Common effect model 5393 $\diamond$ 0.25 $[0.24; 0.26]$ 1.0% Random effects model Heterogeneity: $l^2 = 96\%$ , $\tau^2 = 0.0039$ , $p < 0.01$ Endpoint = America Lu 2017(IFR ) 3415 6830 + 0.01 Endpoint = America Lu 2017(IFR ) 3415 6830 + 0.01 Heterogeneity: $l^2 = 96\%$ , $\tau^2 = 0.039$ , $p < 0.01$ Endpoint = America Lu 2017(IFR ) 3415 6830 + 0.01 Heterogeneity: $l^2 = 90\%$ , $\tau^2 = 0.039$ , $q < 0.01$ Endpoint = America Lu 2017(IFR ) 3415 6830 + 0.01 Heterogeneity: $l^2 = 90\%$ , $\tau^2 = 0.039$ , $q < 0.01$ Endpoint = America Lu 2017(IFR ) 3415 6830 + 0.01 Heterogeneity: $l^2 = 90\%$ , $\tau^2 = 0.0039$ , $p < 0.01$ Endpoint = Am
$\begin{array}{cccccccccccccccccccccccccccccccccccc$
Kasivisvanathan 2016       1956       5387       +       0.36       [0.35; 0.38]       0.8%       4.8%         Wan 2020       189       881       -       0.21       [0.19; 0.24]       0.2%       4.7%         Rogers 2008       26       322       -       0.08       [0.05; 0.12]       0.1%       4.7%         Schatz 2023       42       341       0.12       [0.09; 0.16]       0.1%       4.7%         Meybohm 2020       1372       7939       +       0.17       [0.16; 0.18]       1.8%       4.8%         Common effect model       26128       •       0.18       [0.18; 0.18]       6.0%          Random effects model       267       2394       •       0.17       [0.13; 0.37]       0.1%       4.7%         Abdullah 2017       567       2394       •       0.22       [0.21; 0.24]       0.4%       4.8%         Common effect model       5393       •       0.25       [0.24; 0.26]       1.0%          Random effects model       5393       •       0.25       [0.24; 0.26]       1.0%          Heterogeneity: $l^2$ = 96%, $\tau^2$ = 0.0039, $p < 0.01$ •       •       0.50       [0.4%; 0.51]       0
Wan 2020       189       881        0.21 $[0.19; 0.24]$ 0.2%       4.7%         Rogers 2008       26       322        0.08 $[0.05; 0.12]$ 0.1%       4.7%         Schatz 2023       42       341       0.12 $[0.09; 0.16]$ 0.1%       4.7%         Meybohm 2020       1372       7939       +       0.17 $[0.18]$ $0.8%$ 4.8%         Common effect model       26128       •       0.17 $[0.18]$ $0.8%$ $$ Random effects model       26128       •       0.17 $[0.13; 0.22]$ $$ $52.3\%$ Heterogeneity: $l^2 = 99\%$ , $\tau^2 = 0.0054$ , $p < 0.01$ +       0.34 $[0.31; 0.37]$ $0.1\%$ $4.7\%$ Abdullah 2017       567       2394       +       0.22 $[0.21; 0.24]$ $0.4\%$ $4.8\%$ Common effect model       5393       -       0.25 $[0.4\%; 0.51]$ $0.9\%$ $4.8\%$ Common effects model       5393       +       0.50 $[0.48; 0.52]$ $0.3\%$ $4.8\%$ Common effect model       5393       +       0.50 $[0.48; 0.52]$ $0.3\%$
Rogers 2008       26 $322 \rightarrow - +$ $0.08$ $[0.05; 0.12]$ $0.1\%$ $4.7\%$ Schatz 2023 $42$ $341$ $- + + + + + + + + + + + + + + + + + + +$
Schatz 2023 42 341 Meybohm 2020 1372 7939 Common effect model 26128 Random effects model Heterogeneity: $l^2 = 99\%$ , $\tau^2 = 0.0054$ , $p < 0.01$ Endpoint = Asia Xiong 2023 342 1005 Abdullah 2017 567 2394 Abdullah 2019 445 1994 Common effect model 5393 Random effects model Heterogeneity: $l^2 = 96\%$ , $\tau^2 = 0.0039$ , $p < 0.01$ Endpoint = America Lu 2017(IFR) 3415 6830 Lu 2017(IFR) 1325 2650 Gu 2020 38388 293043 Greenky 2012 2991 15722 + Duarte 2021 72 234 t = 0.0039, $p < 0.01t = 0.017 [0.16; 0.18] 1.8% 4.8%0.13 [0.13; 0.37] 0.1% 4.7%0.34 [0.31; 0.37] 0.1% 4.7%0.34 [0.31; 0.37] 0.1% 4.8%0.22 [0.21; 0.24] 0.4% 4.8%0.25 [0.24; 0.26] 1.0%0.27 [0.19; 0.34]$ 14.3% t = 0.50 [0.48; 0.52] 0.3% 4.8% 0.13 [0.13; 0.13] 84.2% 4.8%
Meybohm 2020       1372       7939       +       0.17       [0.16; 0.18]       1.8%       4.8%         Common effect model       26128 $\diamond$ 0.17       [0.16; 0.18]       1.8%       4.8%         Random effects model       26128 $\diamond$ 0.18       [0.18; 0.18]       6.0%          Heterogeneity: $l^2 = 99\%$ , $r^2 = 0.0054$ , $p < 0.01$ $\bullet$ 0.34       [0.31; 0.37]       0.1%       4.7%         Abdullah 2017       567       2394 $\bullet$ 0.22       [0.21; 0.24]       0.4%       4.8%         Common effect model       5393 $\bullet$ 0.25       [0.24; 0.22; 0.25]       0.4%       4.8%         Common effects model       5393 $\bullet$ 0.25       [0.24; 0.26]       1.0%          Random effects model       5393 $\bullet$ 0.25       [0.24; 0.26]       1.0%          Heterogeneity: $l^2 = 96\%$ , $r^2 = 0.0039$ , $p < 0.01$ $\bullet$ $\bullet$ 0.50       [0.49; 0.51]       0.9%       4.8%         Lu 2017(IFR)       3415       6830 $\bullet$ $\bullet$ 0.50       [0.48; 0.52]       0.3%       4.8%         Guazo 38388       293043 $\bullet$ $\bullet$ $\bullet$ <
Common effect model       26128 $\bullet$ 0.18 [0.18; 0.18]       6.0%          Random effects model        0.17 [0.13; 0.22]        52.3%         Heterogeneity: $l^2 = 99\%$ , $\tau^2 = 0.0054$ , $p < 0.01$ 0.34 [0.31; 0.37]       0.1%       4.7%         Abdullah 2017       567       2394        0.24 [0.22; 0.25]       0.4%       4.8%         Abdullah 2019       445       1994        0.25 [0.24; 0.26]       1.0%          Random effects model       5393        0.25 [0.24; 0.26]       1.0%          Heterogeneity: $l^2 = 96\%$ , $\tau^2 = 0.0039$ , $p < 0.01$ 0.27 [0.19; 0.34]        14.3%         Heterogeneity: $l^2 = 96\%$ , $\tau^2 = 0.0039$ , $p < 0.01$ 0.50 [0.48; 0.52]       0.3%       4.8%         Lu 2017(IFR)       3415 6830                Endpoint = America                            -
Random effects model       0.17 $[0.13; 0.22]$ 52.3%         Heterogeneity: $l^2 = 99\%$ , $\tau^2 = 0.0054$ , $p < 0.01$ 52.3%         Endpoint = Asia        0.34 $[0.31; 0.37]$ 0.1% 4.7%         Abdullah 2017       567 2394        0.24 $[0.22; 0.25]$ 0.4% 4.8%         Abdullah 2019       445 1994        0.22 $[0.21; 0.24]$ 0.4% 4.8%         Common effect model       5393        0.25 $[0.24; 0.26]$ 1.0%         Random effects model       5393        0.27 $[0.19; 0.34]$ 14.3%         Heterogeneity: $l^2 = 96\%$ , $\tau^2 = 0.0039$ , $p < 0.01$ +       0.50 $[0.49; 0.51]$ 0.9% 4.8%       0.3888 293043           Greenky 2012       2991 15722       +       -       0.50 $[0.18; 0.20]$ 3.3% 4.8%       0.31 $[0.25; 0.37]$ 0.0% 4.5%
Heterogeneity: $l^2 = 99\%$ , $\tau^2 = 0.0054$ , $p < 0.01$ Endpoint = Asia Xiong 2023 342 1005 Abdullah 2017 567 2394 Abdullah 2019 445 1994 Common effect model 5393 Random effects model Heterogeneity: $l^2 = 96\%$ , $\tau^2 = 0.0039$ , $p < 0.01$ Endpoint = America Lu 2017(IFR) 3415 6830 Lu 2017(IFR) 1325 2650 Gu 2020 38388 293043 Greenky 2012 2991 15722 + Duarte 2021 72 234 +
Endpoint = Asia Xiong 2023 342 1005 Abdullah 2017 567 2394 Abdullah 2019 445 1994 Common effect model 5393 Random effects model Heterogeneity: $l^2 = 96\%$ , $\tau^2 = 0.0039$ , $p < 0.01$ Endpoint = America Lu 2017(IFR) 3415 6830 Lu 2017(IR) 1325 2650 Gu 2020 38388 293043 Greenky 2012 2991 15722 + 0.50 [0.49; 0.51] 0.9% 4.8% Duarte 2021 72 234 + 0.50 [0.49; 0.51] 0.9% 4.8% - 0.27 [0.19; 0.34] 14.3%
Xiong 2023 $342 \ 1005$ $0.34 \ [0.31; 0.37]$ $0.1\%$ $4.7\%$ Abdullah 2017 $567 \ 2394$ + $0.24 \ [0.22; 0.25]$ $0.4\%$ $4.8\%$ Abdullah 2019 $445 \ 1994$ - $0.22 \ [0.21; 0.24]$ $0.4\%$ $4.8\%$ Common effect model $5393$ • $0.25 \ [0.24; 0.26]$ $1.0\%$ Random effects model $5393$ • $0.25 \ [0.24; 0.26]$ $1.0\%$ Heterogeneity: $I^2 = 96\%$ , $\tau^2 = 0.0039$ , $p < 0.01$ + $0.50 \ [0.49; 0.51]$ $0.9\%$ $4.8\%$ Lu 2017(IFR) $3415 \ 6830$ + $0.50 \ [0.48; 0.52]$ $0.3\%$ $4.8\%$ Gu 2020 $38388 \ 293043$ + $0.50 \ [0.48; 0.52]$ $0.3\%$ $4.8\%$ Greenky 2012 $2991 \ 15722$ + $0.31 \ [0.25; 0.37]$ $0.0\%$ $4.5\%$ Duarte 2021 $72 \ 234$ + $$ $0.31 \ [0.25; 0.37]$ $0.0\%$ $4.5\%$
Abdullah 2017 $567$ $2394$ + $0.24$ $[0.22; 0.25]$ $0.4\%$ $4.8\%$ Abdullah 2019 $445$ $1994$ + $0.22$ $[0.21; 0.24]$ $0.4\%$ $4.8\%$ Common effect model $5393$ $\diamond$ $0.25$ $[0.24; 0.26]$ $1.0\%$ Random effects model $5393$ $\diamond$ $0.25$ $[0.24; 0.26]$ $1.0\%$ Heterogeneity: $l^2 = 96\%$ , $\tau^2 = 0.0039$ , $p < 0.01$ $\bullet$ $0.27$ $[0.19; 0.34]$ $14.3\%$ Lu 2017(IFR) $3415$ $6830$ + $0.50$ $[0.49; 0.51]$ $0.9\%$ $4.8\%$ Gu 2020 $38388$ $293043$ 1 $0.50$ $[0.48; 0.52]$ $0.3\%$ $4.8\%$ Greenky 2012 $2991$ $15722$ + $0.31$ $[0.25; 0.37]$ $0.0\%$ $4.5\%$
Abdullah 2019       445       1994        0.22 $[0.21; 0.24]$ 0.4%       4.8%         Common effect model       5393        0.25 $[0.24; 0.26]$ 1.0%          Random effects model        0.27 $[0.19; 0.34]$ 14.3%         Heterogeneity: $l^2 = 96\%$ , $\tau^2 = 0.0039$ , $p < 0.01$ +       0.50 $[0.49; 0.51]$ 0.9%       4.8%         Lu 2017(IFR)       3415       6830       +       0.50 $[0.48; 0.52]$ 0.3%       4.8%         Gu 2020       38388       293043       -       -       0.13 $[0.13; 0.13]$ $84.2\%$ 4.8%         Greenky 2012       2991       15722       +       -       0.31 $[0.25; 0.37]$ 0.0%       4.5%
Common effect model5393 Random effects model Heterogeneity: $J^2 = 96\%$ , $\tau^2 = 0.0039$ , $p < 0.01$ $\diamond$ $0.25 [0.24; 0.26]$ $0.27 [0.19; 0.34]$ $$ $14.3\%$ Endpoint = America Lu 2017(IR) $3415 6830$ $1325 2650$ Gu 2020 $+$ $0.50 [0.49; 0.51]$ $ 0.9\%$ $4.8\%$ $0.13 [0.13; 0.13]$ $84.2\%$ $4.8\%$ $0.13 [0.13; 0.13]$ $84.2\%$ $4.8\%$ $0.19 [0.18; 0.20]$ $3.3\%$ $4.8\%$ $0.31 [0.25; 0.37]$ $0.0\%$ $0.0\%$
Random effects model Heterogeneity: $l^2 = 96\%$ , $\tau^2 = 0.0039$ , $p < 0.01$ 0.27 [0.19; 0.34]14.3%Endpoint = America Lu 2017(IR)3415 6830 1325 2650 Gu 2020+0.50 [0.49; 0.51] 0.50 [0.48; 0.52] 0.13 [0.13; 0.13]0.9% 84.2% 84.8% 0.13 [0.13; 0.13]84.2% 84.2% 84.8% 0.19 [0.18; 0.20]3.3% 3.3% 4.8%Duarte 202172 234+0.31 [0.25; 0.37] 0.0%0.0%
Heterogeneity: $l^2 = 96\%$ , $\tau^2 = 0.0039$ , $p < 0.01$ Endpoint = America Lu 2017(IFR) 3415 6830 Lu 2017(IR) 1325 2650 Gu 2020 38388 293043 Greenky 2012 2991 15722 + 0.13 [0.13; 0.13] 84.2% 4.8% Greenky 2012 2991 15722 + 0.31 [0.25; 0.37] 0.0% 4.5%
Endpoint = America         Lu 2017(IFR)       3415       6830       +       0.50       [0.49; 0.51]       0.9%       4.8%         Lu 2017(IR)       1325       2650       -+       0.50       [0.48; 0.52]       0.3%       4.8%         Gu 2020       38388       293043       -+       0.13       [0.13; 0.13]       84.2%       4.8%         Greenky 2012       2991       15722       +       0.19       [0.18; 0.20]       3.3%       4.8%         Duarte 2021       72       234        0.31       [0.25; 0.37]       0.0%       4.5%
Lu 2017(IFR)       3415       6830       +       0.50       [0.49; 0.51]       0.9%       4.8%         Lu 2017(IR)       1325       2650        0.50       [0.48; 0.52]       0.3%       4.8%         Gu 2020       38388       293043        0.13       [0.13; 0.13]       84.2%       4.8%         Greenky 2012       2991       15722       +       0.19       [0.18; 0.20]       3.3%       4.8%         Duarte 2021       72       234        0.31       [0.25; 0.37]       0.0%       4.5%
Lu 2017(IR)       1325       2650       -+       0.50       [0.48; 0.52]       0.3%       4.8%         Gu 2020       38388       293043       I       0.13       [0.13; 0.13]       84.2%       4.8%         Greenky 2012       2991       15722       +       0.19       [0.18; 0.20]       3.3%       4.8%         Duarte 2021       72       234        0.31       [0.25; 0.37]       0.0%       4.5%
Gu 2020       38388 293043       •       0.13       [0.13; 0.13]       84.2%       4.8%         Greenky 2012       2991       15722       +       0.19       [0.18; 0.20]       3.3%       4.8%         Duarte 2021       72       234        0.31       [0.25; 0.37]       0.0%       4.5%
Greenky 2012         2991         15722         +         0.19         [0.18; 0.20]         3.3%         4.8%           Duarte 2021         72         234          0.31         [0.25; 0.37]         0.0%         4.5%
Duarte 2021         72         234          0.31         [0.25; 0.37]         0.0%         4.5%
Bailey 2021 817 5384 + 0.15 [0.14; 0.16] 1.4% 4.8%
Viola 2015         2576         13563         +         0.19         [0.18; 0.20]         2.9%         4.8%
Common effect model 337426 0.14 [0.14; 0.14] 93.0%
Random effects model 0.28 [0.16; 0.40] 33.3%
Heterogeneity: $l^2 = 100\%$ , $\tau^2 = 0.0254$ , $p = 0$
Common effect model 368947 0.14 [0.14; 0.14] 100.0%
Random effects model         0.22 [0.17; 0.27]          100.0%
Heterogeneity: $I^2 = 100\%$ , $\tau^2 = 0.0136$ , $p = 0$ 0.1 0.2 0.3 0.4 0.5 Test for subgroup differences (common effect): $\gamma_2^2 = 590.48$ , df = 2 ( $p < 0.01$ )

Test for subgroup differences (common effect):  $\chi_2^2 = 590.48$ , df = 2 (p < 0.01) Test for subgroup differences (random effects):  $\chi_2^2 = 6.46$ , df = 2 (p = 0.04)

**Fig. 4** Prevalence of preoperative anaemia in different continents

(5)DVT

Four studies [14, 17, 30, 31] reported the effect of preoperative anemic versus non-anemic patients on postoperative DVT, using a random-effects model to create a forest plot showing that preoperative anemic patients had a 2.23-fold risk of DVT compared with preoperative non-anemic patients ( RR = 2.23, 95% CI [0.61, 8.13], P = 0.0001,  $I^2 = 100\%$ ) (Fig. 13) (The results of sensitivity analysis are shown in Additional file 4Annex 4).

(6) Number of days in hospital

Ten studies [1, 14, 24, 31, 32, 34, 36, 38–40] reported the effect of preoperative anemic versus non-anemic patients on the number of days in the hospital, using a

	_			_		Weight	Weight
Study	Events	Total		Proportion	95%-CI	(common)	(random)
Endpoint = male							
Duarte 2021	27	99	·	0.27	[0.19; 0.37]	0.0%	2.9%
Greenky 2012	1134	5360	+	0.21	[0.20; 0.22]	1.1%	3.2%
Schatz 2023	21	147	<del></del>	0.14	[0.09; 0.21]	0.0%	3.1%
Bailey 2021	311	2417	+	0.13	[0.12; 0.14]	0.7%	3.2%
Xiong 2023	68	144	· · · · · · · · · · · · · · · · · · ·	0.47	[0.39; 0.56]	0.0%	2.9%
Myers 2004	21	135		0.16	[0.10; 0.23]	0.0%	3.0%
Jans 2014	401	2936	4	0.14	[0.12; 0.15]	0.8%	3.2%
Lu 2017(IFR)	1510	3016	+	0.50	[0.48; 0.52]	0.4%	3.2%
Lu 2017(IR)	770	1364		- 0.56	[0.54; 0.59]	0.2%	3.2%
Kasivisvanathan 2016	794	2409	+	0.33	[0.31; 0.35]	0.4%	3.2%
Wan 2020	66	348		0.19	[0.15; 0.23]	0.1%	3.1%
Gu 2020	21667	175158		0.12	[0.12; 0.13]	54.1%	3.2%
Greenky 2012	1134	5360	+		[0.20; 0.22]		3.2%
Rogers 2008	2	141 -	<b>←</b>	0.01	[0.00; 0.05]	0.3%	3.2%
Abdullah 2019	134	473	· · · ·	0.28	[0.24; 0.33]		3.1%
Viola 2015	1057	5962	+	0.18	[0.17; 0.19]		3.2%
Common effect model		205469	1	0.13	[0.13; 0.13]	60.7%	
Random effects mode				0.24	[0.17; 0.32]		49.9%
Heterogeneity: $I^2 = 100\%$	$\tau^2 = 0.023$	0, p = 0					
Endpoint = female							
Duarte 2021	45	135		0.33	[0.25; 0.42]	0.0%	2.9%
Greenky 2012	1857	6870	+		[0.26; 0.28]	1.2%	3.2%
Bailey 2021	505	2967			[0.16; 0.18]		3.2%
Xiong 2023	242	476			[0.46; 0.55]	0.1%	3.1%
Myers 2004	14	90			[0.09; 0.25]	0.0%	3.0%
Jans 2014	261	2229	+!		[0.10; 0.13]		3.2%
Lu 2017(IFR)	1905	3814	+		[0.48; 0.52]	0.5%	3.2%
Lu 2017(IR)	586	1286	¦		[0.43; 0.48]	0.2%	3.2%
Kasivisvanathan 2016	1162	2978	-		[0.37; 0.41]	0.4%	3.2%
Wan 2020	123	533	·		[0.20; 0.27]	0.1%	3.1%
Gu 2020	16994	118258			[0.14; 0.15]	32.2%	3.2%
Greenky 2012	1857	6870	+		[0.26; 0.28]	1.2%	3.2%
Rogers 2008	24	181	<b>!</b>	0.13	[0.09; 0.19]	0.1%	3.1%
Schatz 2023	21	194	<u> </u>	0.11	[0.07; 0.16]		3.1%
Abdullah 2019	311	1521	¦ +	0.20	[0.18; 0.23]	0.3%	3.2%
Viola 2015	1519	7601	+		[0.19; 0.21]	1.6%	3.2%
Common effect model		156003	1		[0.16; 0.17]	39.3%	
Random effects mode					[0.20; 0.33]		50.1%
Heterogeneity: $I^2 = 100\%$ ,	$\tau^2 = 0.018$	3, p = 0					
Common effect model		361472		0 15	[0.14; 0.15]	100.0%	
Random effects mode					[0.20; 0.30]		100.0%
	-				[====; ====]		
Heterogeneity: $I^2 = 100\%$	$\tau^2 = 0.020$	1, <i>p</i> = 0	0.1 0.2 0.3 0.4 0.5				
Test for subgroup difference	ces (commo	on effect):	$\chi_1^2$ = 651.31, df = 1 ( $p < 0.01$ )				

Test for subgroup differences (common effect):  $\chi_1^2 = 651.31$ , df = 1 (p < 0.01) Test for subgroup differences (random effects):  $\chi_1^2 = 0.13$ , df = 1 (p = 0.72)

Fig. 5 Prevalence of preoperative anaemia by gender

random-effects model to create a forest plot, and their results showed that preoperative anemic patients had increased the risk of patient days in hospital when compared with preoperative non-anemic patients (MD = 1.57,

95% CI [1.04, 2.10], P < 0.01,  $I^2 = 97\%$ ,) (Fig. 14) (The results of sensitivity analysis are shown in Additional file 4Annex 4).

Study		Odds Ratio	OR	95%-CI	P−value	Tau2	Tau	12
Omitting Xiong 2023 Omitting Myers 2004				[0.62; 18.90] [0.59; 18.37]			2.4151 2.4354	
Omitting Jans 2014 Omitting Lu 2017(IFR)			— 3.22	[0.57; 18.35] [0.61; 18.88]	0.19	6.0619	2.4621 2.4245	97%
Omitting Lu 2017(IR)		-	— 3.24	[0.57; 18.41]	0.18	6.0515	2.4600	97%
Omitting Kasivisvanathan 2016 Omitting Gu 2020 THA				[0.57; 18.42] [0.55; 18.00]			2.4598 2.4714	
Omitting Gu 2020 TKA Omitting Greenky 2012		=		[0.55; 18.09] [1.18; 1.76]			2.4697 0.2611	
Random effects model	[		- 2.84	[0.67; 12.14]	0.16	4.7361	2.1763	96%
	0.1	0.5 1 2 10	C					

Fig. 6 Prevalence of hypertension


Study	Events	exp Total	Events	control Total
Jans 2014	108	658	475	4432
Lu 2017(IFR)	771	3415	781	3415
Lu 2017(IR)	349	1325	193	1325
Kasivisvanathan 2016	367	1956	387	3431
Gu 2020 THA	2873	14751	10529	94215
Gu 2020 TKA	6915	23637	26859	160440
Greenky 2012	405	2991	986	12231
Abdullah 2019	11	318	24	1549
Random effects model Heterogeneity: $J^2 = 96\%$ r	<sup>2</sup> – 0 0420	<b>49051</b>	01	281038


Heterogeneity:  $I^2 = 96\%$ ,  $\tau^2 = 0.0429$ , p < 0.01

Fig. 7 Prevalence of diabetes mellitus

Study	Events	exp Total	Events	control Total
Jans 2014	53	655	330	4463
Lu 2017(IFR)	266	3415	251	3415
Lu 2017(IR)	104	1325	76	1325
Kasivisvanathan 2016	180	1956	305	3431
Gu 2020 THA	870	14751	3308	94215
Gu 2020 TKA	1147	23637	5494	160440
Greenky 2012	195	2991	886	12231
<b>Random effects model</b> Heterogeneity: $I^2 = 93\%$ , $\tau$		<b>48730</b> 3, <i>p</i> < 0.1	01	279520

Fig. 8 Prevalence of Chronic Obstructive Pulmonary Disease (COPD)





Study	Events	exp Total	c Events	ontrol Total	Risk Ratio	RR	95%-Cl Weight
Lu 2017(IFR) Lu 2017(IR) Wan 2020 Greenky 2012	120 9 130	3415 1325 189 2991		1325 692 12231		1.40 1.94 2.05	[1.18; 2.33]24.1%[1.07; 1.82]30.2%[0.88; 4.28]7.1%[1.67; 2.52]36.2%
Bailey 2021 Random effects model Heterogeneity: $I^2 = 53\%$ , $\tau$		8737		4524 22187	0.2 0.5 1 2 5		[0.11; 1.95] 2.4% [1.33; 2.09] 100.0%

Fig. 9 Postoperative deep infection

Study	Events	exp Total	Events	control Total	Risk Ratio	RR	95%-Cl Weight
Lu 2017(IFR)	33	3415	36	3415		0.92	[0.57; 1.47] 18.9%
Lu 2017(IR)	20	1325	20	1325		1.00	[0.54; 1.85] 14.3%
Gu 2020 THA	205	11837	948	94215		1.72	[1.48; 2.00] 32.2%
Gu 2020 TKA	246	19183	1248	160440		1.65	[1.44; 1.89] 32.6%
Bailey 2021	1	817	10	4524		0.55	[0.07; 4.32] 2.0%
<b>Random effects model</b> Heterogeneity: $I^2 = 59\%$ , $\tau$		<b>36577</b>	05	263919		1.36	[1.01; 1.84] 100.0%
	- 0.0000	σ, μ = 0.	00		0.1 0.5 1 2	10	

Fig. 10 Postoperative superficial infection

Study	Events	exp Total	Events	control Total		Risk I	Ratio	RR	95%-CI	Weight
Xiong 2023	25	35	20	190				6.79	[4.26; 10.80]	7.5%
Jans 2014	209	662	363	4503			-+-	3.92	[3.37; 4.55]	7.9%
Lu 2017(IFR)	1272	3415	616	3415			+	2.06	[1.90; 2.25]	8.0%
Lu 2017(IR)	485	1325	251	1325			+-	1.93	[1.69; 2.20]	7.9%
Kasivisvanathan 2016	1212	1956	822	3431			+	2.59	[2.41; 2.77]	8.0%
Evans 2011	7	15	10	154				- 7.19	[3.21; 16.11]	6.7%
Wan 2020	116	189	102	692			-+	4.16	[3.37; 5.15]	7.9%
Gu 2020 THA	4793	94215	2962	11837	+			0.20	[0.20; 0.21]	8.0%
Gu 2020 TKA	3030	19183	5034	160440			+	5.03	[4.82; 5.25]	8.0%
Duarte 2021	25	72	9	162			· · ·	6.25	[3.07; 12.71]	7.0%
Abdullah 2019	40	318	36	1549			<b></b> +	5.41	[3.51; 8.35]	7.6%
Bailey 2021	63	817	52	4524				6.71	[4.68; 9.61]	7.7%
Viola 2015	375	2576	537	10987				2.98	[2.63; 3.37]	7.9%
Random effects model Heterogeneity: $I^2 = 100\%$ ,		<b>124778</b> 4, p = 0		203209	ſ			3.23	[1.91; 5.47]	100.0%
					0.1	0.5 1	1 2 10			

Fig. 11 Postoperative blood transfusion rates

			exp			control			
Study	Total	Mean	SD	Total	Mean	SD	Mean Difference	MD	95%-CI Weight
Lasocki 2015	131	2.40	1.5000	395	2.20	1.4000		- 0.20	[-0.09; 0.49] 25.3%
Jans 2014	662	2.00	1.4800	4503	2.00	1.1800		0.00	[-0.12; 0.12] 37.6%
Duarte 2021	72	2.76	0.4200	162	3.00	0.5300	— <b>·</b> — <b>·</b>	-0.24	[-0.37; -0.11] 37.1%
Random effects model	865			5060				-0.04	[-0.27; 0.20] 100.0%
Heterogeneity: $I^2 = 82\%$ , $\tau^2$	$^{2} = 0.03$	846, p <	0.01						
							-0.4 -0.2 0 0.2 0.4		
Fig. 12 Postoperative bloo	d transf	usions							

Study	Events	exp Total	Events	control Total
Xiong 2023	30	310	16	310
Lu 2017 THA(IFR)	27	3415	21	3415
Lu 2017 THA(IR)	21	1325	14	1325
Gu 2020THA	530	94215	93	11837
Gu 2020TKA	1926	19183	309	160440
Greenky 2012	50	2991	233	12231
Random effects model		121439		189558
Heterogeneity: $I^2 = 100\%$ ,	$\tau^2 = 2.551$	9, $p = 0$		




Fig. 13 DVT

Study	Total Mea	exp an SD	Total	co Mean	ontrol SD	Mean Di	ifference	MD	95%-CI	Weight
Lasocki 2015	174 11.	70 9.6000	1161	8.80 5.	.9000			- 2.90	[1.43; 4.37]	5.6%
Jans 2014	662 3.0	00 7.3000	4503	2.00 7.	.3000			1.00	[0.40; 1.60]	8.8%
Lu 2017(IFR)	3415 4.9	90 5.2000	3415	3.80 7.	.1000		-	1.10	[0.80; 1.40]	9.6%
Lu 2017(IR)	1325 7.3	30 7.8000	1325	4.80 5.	.1000			2.50	[2.00; 3.00]	9.1%
Kasivisvanathan 2016	1956 16.0	00 2.9600	3431	14.00 2.	.9600		+	2.00	[1.84; 2.16]	9.8%
Wan 2020	189 4.4	40 3.3000	692	3.10 1.	.6000			1.30	[0.81; 1.79]	9.1%
Greenky 2012	2991 4.3	35 4.8000	12231	3.99 4.	.8000		+	0.36	[0.17; 0.55]	9.8%
Duarte 2021	72 6.4	1.2000	162	3.36 0.	.3000		-	3.12	[2.84; 3.40]	9.6%
Bailey 2021	817 4.	50 5.0000	4524	2.70 2.	.5000			1.80	[1.45; 2.15]	9.5%
Meybohm 2020	1327 12.0	00 5.1900	6648	11.00 2.	.9600		•	1.00	[0.71; 1.29]	9.6%
Viola 2015	2576 4.0	9.8500	10987	3.33 9.	.8500		-	0.71	[0.29; 1.13]	9.3%
<b>Random effects model</b> Heterogeneity: $I^2 = 97\%$ , $\tau$		< 0.01	49079		Г			1.57	[1.04; 2.10]	100.0%
					-4	-2 (	024			

**Fig. 14** Forest plot of hospitalisation days

## (7) Re-hospitalisation rate within three months

Five studies reported on the effect of preoperative anemic versus non-anemic patients on readmission rates within 3 months [1, 14, 17, 38, 39], due to large heterogeneity ( $I^2 = 100\%$ ) using a random-effects model to create a forest plot, the results of which showed that patients with preoperative anemia would be at significantly greater risk of readmission rates compared with patients with preoperative non-anemia (RR = 2.57, 95% CI [1.03, 6.43], P < 0.04,  $I^2 = 100\%$ ) (Fig. 15) (The results of sensitivity analysis are shown in Additional file 4Annex 4).

## (8) Mortality

Seven studies [17, 24, 31, 32, 36, 39, 40] reported on the effect of preoperative anemic versus non-anemic patients on postoperative mortality. Because of the high

		exp		control	
Study	Events	Total	Events	Total	
Jans 2014	222	662	437	4503	
Lu 2017(IFR)	207	3415	186	3415	
Lu 2017(IR)	115	1325	82	1325	
Gu 2020 THA	1699	11837	386	94215	
Gu 2020 TKA	382	19183	1660	160440	
Duarte 2021	8	72	17	162	
Bailey 2021	35	817	111	4524	
Common effect model		37311		268584	
Random effects model Heterogeneity: $I^2 = 100\%$ ,	$\tau^2 = 1.498$	33, p = 0	)		

Risk Ratio	RR	95%-CI	(common)	(random)
*		[ 3.01; 3.97] [ 0.92; 1.35] [ 1.07; 1.84] [31.42; 39.06] [ 1.72; 2.15] [ 0.48; 2.34] [ 1.20; 2.53]	12.9% 21.5% 9.5% 10.0% 41.0% 1.2% 3.9%	14.5% 14.5% 14.4% 14.6% 14.6% 13.2% 14.3%
0.1 0.5 1 2 10	5.18 2.57		100.0% 	 100.0%

Fig. 15 Forest plot of readmission rates within three months

Study	Events	exp Total	Events	control Total	Risk Ratio	RR	95%-CI	Weight
Kasivisvanathan 2016 Wan 2020 Gu 2020 THA Gu 2020 TKA Greenky 2012 Duarte 2021 Meybohm 2020 Viola 2015		1956 189 11837 19183 2991 72 1327 2576	9 5 87 129 88 2 60 9	3431 692 94215 160440 12231 162 6648 10987		4.39   4.21 4.08 2.51 2.25   6.10	[2.58; 11.54] [1.36; 14.24] [2.95; 6.01] [3.02; 5.52] [1.79; 3.51] [0.32; 15.66] [4.35; 8.53] [0.79; 7.06]	9.3% 4.7% 18.9% 20.7% 19.6% 1.9% 19.6% 5.3%
<b>Random effects mode</b> Heterogeneity: $l^2 = 55\%$ , a	-	<b>40131</b> ), <i>p</i> = 0.1		288806	0.1 0.5 1 2 10	4.00	[3.02; 5.29]	100.0%

Fig. 16 Mortality forest map

heterogeneity ( $I^2$ =55%), a random effects model was used to create a forest plot, the results of which showed that preoperative anemic patients would substantially increase the risk of mortality in patients compared with preoperative non-anemic patients (RR=4.00, 95% CI [3.02, 5.29], *P*=0.03) (Fig. 16) (The results of sensitivity analysis are shown in Additional file 4Annex 4).

## Other patient-reported outcomes

Two studies [25, 35] reported common causes of preoperative anemia; however, they were not combined because of the small number of included studies and missing standard deviations because the studies did not provide complete data. Therefore, only a systematic evaluation of the common causes of preoperative anemia was performed, and both studies came to a similar conclusion that the most common cause of preoperative anemia was iron deficiency anemia and that preoperative treatment of iron deficiency anemia was associated with an improved prognosis and a reduction in allogeneic transfusions.

## Grading of evidence

The overall quality of evidence was low given the observational design of the included studies. Evidence for all outcomes was of low quality owing to the stage of the study, imprecision of effect sizes, study limitations, inconsistency, or publication bias (Table 3).

## Discussion

Preoperative anemia is a common and significant risk factor for adverse events after joint replacement. Anemia affects up to 21–35% of patients undergoing primary or revision total joint arthroplasty [4, 32, 41]. The association between preoperative anemia and postoperative complications such as infection, mortality, length of hospital stay, and functional status has been reported in several studies [25, 42–44].

In this study, we found an overall prevalence of preoperative anemia of 22%, which varied considerably by type of surgery, with the highest prevalence of preoperative anemia of 38.3% in patients with TKA awaiting revision,

Maight

Waight

Outcomes	Limitations of the study	Inconsistency I <sup>2</sup> > 50 per cent	Indirectness Yes:↓	inaccuracy	Publication bias Yes or unclear: $\downarrow$	Effect size RR (95% CI) Lower limit RR > 2.0: ↑	Overall quality of evidence
Complicated with hyper- tension	1↓	$l^2 = 100\% \downarrow$	No	No	No	RR = 1.26,95 % CI [1.04,1.53	3] Low
Complicated with diabe- tes mellitus	1↓	$l^2 = 96\%$	↓ No	No	No	RR = 1.59,95 % CI [1.36,1.86	6] Low
Complicated with COPD	1↓	$ ^2=93\%\downarrow$	No	No	No	RR = 1.12, 95 % CI [1.01,1.43]	Low
Postoperative deep infection	1↓	l <sup>2</sup> =53%↓	No	No	No	RR = 1.67, 95 % Cl [1.33,1.95]	Low
Postoperative superficial infection	1↓	l <sup>2</sup> =59% ↓	No	No	No	RR = 1.36, 95 % Cl [1.01,1.84]	Low
Postoperative blood transfusion rate	1↓	$l^2 = 100\% \downarrow$	No	No	No	RR = 1.36, 95 % Cl [1.01,1.84]	Low
Postoperative blood transfusion volume	1↓	$l^2 = 82\% \downarrow$	No	No	No	MD=-0.04, 95 % CI [-0.27,0.20]	Low
DVT	1↓	$l^2 = 100\% \downarrow$	No	Yes↓	No	RR=2.23, 95 % CI [0.61, 8.13] ↑	Low
Hospital days	1↓	$l^2=97$ per cent $\downarrow$	No	No	No	MD=1.66, 95 % CI [1.10, 2.21]	Low
Rehospitalisation rate within three months	1↓	$l^2 = 100\%$	↓No	Yes↓	No	RR=2.57, 95 % CI [1.03, 6.42] ↑	Low
mortality	1↓	$l^2 = 59\% \downarrow$	No	Yes↓	No	RR=4.12, 95 % CI [3.08, 5.51] ↑	Low

## Table 3 Quality of evidence

GRADE grading of recommendations assessment development and evaluation; RR relative risk; MD mean difference

↓ signifies a downgrade in quality of evidence; ↑ signifies an upgrade in quality of evidence

and the lowest prevalence of preoperative anemia of 15.2% in patients undergoing first-time hip arthroplasty. The lowest prevalence was 17.3 percent in Europe, with similar rates in Asia and the Americas (26.6–28.1%).

Gender is an immutable factor for total joint arthroplasty waiting for patients with preoperative anemia. We found that the prevalence of preoperative anemia was slightly higher in women (25.5%) than in men (22.8%) undergoing total joint arthroplasty. There are multiple reasons for this phenomenon. In addition to the lack of androgens in women compared with men, due to the physiological cycle, the different distribution of factors such as diabetes and metabolic syndrome between the sexes may also contribute to this inconsistency [45–47].

To determine the impact of preoperative anemia on patients' surgical outcomes, we summarized previous studies and found that the available studies reported only a limited number (two or three) of crude outcome indicators (e.g., deaths, complications, infections, and myocardial infarction) [32, 34, 39]. Therefore, eight commonly used postoperative evaluation indicators were included in this study to achieve a more detailed and adequate measure of the impact of preoperative anemia on patients' postoperative outcomes.

Comorbidities are common in patients with preoperative anemia, and the majority of older people awaiting joint replacement have three or more comorbidities [14, 17, 24]. Our meta-analysis found statistically significant differences in several preoperative comorbidities (hypertension, diabetes mellitus, and COPD) between the preoperative anemic and preoperative non-anemic groups. However, the results require careful consideration because of the high degree of heterogeneity observed in comorbidity analyses. We performed sensitivity analyses for comorbidities to identify sources of high heterogeneity and found that studies of comorbid hypertension versus comorbid COPD were relatively stable; however, when we performed sensitivity analyses for patients with comorbid diabetes, we found that by removing Lu 2017 (IFR) et al. [14], the heterogeneity was reduced to 0%. Analyzing possible reasons compared to other included studies, Lu 2017 (IFR) et al. [14] performed propensity score matching to control for selection bias, and this article was the only one to show that the risk of preoperative anemia combined with diabetes mellitus was lower than the risk of preoperative non-anemia combined with diabetes mellitus.

Surgical site infection (SSI) is the most common complication. Deep infection around the prosthesis is one of the most serious orthopedic complications in patients and will increase readmission and mortality rates [14, 31, 48, 49]. Our study showed that superficial and deep infections occurred with equal frequency in preoperatively anemic patients, suggesting that preoperative anemic patients have poorer immunity than preoperative non-anemic patients. Therefore, rational use of antibiotics and strict asepsis during the perioperative period in preoperatively anemic patients is essential.

In this study, we assessed the effect of preoperative anemia on postoperative transfusion rates and volumes in patients undergoing elective hip and knee arthroplasty. Our findings are consistent with the published literature showing that preoperative anemia negatively affects individual transfusion risk [1, 14, 24, 39]. Meta-analysis of the study showed that the preoperative anemic group had a higher risk of postoperative transfusion rate than the preoperative non-anemic group (RR = 3.23), but there was no statistically significant difference in the volume of transfusion between the two groups postoperatively; however, the number of inclusions and heterogeneity  $I^2$ was large, and this result should be viewed carefully. In addition, although transfusions are undoubtedly necessary for patients with acute anemia, they have deleterious effects, including transfusion-associated lung injury, hospital-acquired infections, volume overload, immunomodulation, and delayed physiotherapy in transfusion recipients [50, 51]. Finally, preoperative anemia reduces physiological oxygen-carrying capacity, which in turn impairs other organ systems such as cardiac perfusion, lung function, and wound healing, and blood, an increasingly scarce product that is dependent on voluntary donors, must be used in a restrictive and rational manner with attention to the need to treat anemia preoperatively.

DVTof the lower extremities is a common complication after joint replacement surgery. Iron deficiency anemia is an independent predictor of VTE recurrence in patients with unexplained thrombosis [52], and patients are at high risk of VTE after joint replacement surgery [53]. In the absence of pharmacological intervention, the incidence of asymptomatic deep vein thrombosis after TKA ranges from 40 to 85%, and the incidence of fatal PE ranges from 0.87 to 1.99% [54]. Preoperative anemia has been reported to increase blood volume and blood substances [55–58]. Therefore, patients with preoperative anemia must be thoroughly investigated and hypercoagulability controlled when undergoing TKA or THA. Arranging relevant anticoagulation therapy and encouraging patients to exercise early may reduce the recurrence of DVT and serious complications.

We found that preoperative anemia was associated with length of hospital stay and readmission rates. The more severe the anemia, the longer the hospital stay, the worse the outcome, and the higher the cost. International guidelines recommend early detection of preoperative anemia, identification of the cause, and treatment of any potentially reversible causes, such as iron deficiency. Treatment of anemia has been shown to reduce postoperative blood transfusions, length of hospital stay, and 30-day readmission rates. A previous study reported that preoperative intravenous iron treatment of iron deficiency anemia in patients undergoing major abdominal surgery reduced the median hospital stay by 3 days [59]. Similar results have been achieved with elective lower limb arthroplasty in the United Kingdom and Australia [60]. Abdullah et al. showed that each 1-g increase in preoperative Hb reduced the patient's hospital stay by 0.2 days. It is therefore necessary to go further and examine the range of postoperative effects of preoperative treatment of anemia, and again the importance of preoperative treatment of anemia [33].

To the best of our knowledge, the effect of preoperative anemia on mortality in patients undergoing orthopedic surgery has been controversial in recent years. In our meta-analysis, forest plots showed 389 deaths out of 288,806 patients in the preoperative non-anemic group, a mortality rate of 0.13%, compared with 277 deaths out of 40,131 patients in the preoperative anemic group, a mortality rate of 0.7%. The difference in mortality after lower limb arthroplasty between the two groups was significant, with preoperative anemia having a 4.00 times risk of mortality compared to preoperative non-anemic patients. However, our findings on mortality should be watched carefully because of the large heterogeneity in results ( $I^2 = 55\%$ ).

Age is also a widely accepted risk factor for preoperative anemia. Large-population studies have shown that the prevalence of preoperative anemia increases with age [61–63]. Our preliminary study did not report prevalence rates in different age groups; therefore, we were unable to pool the prevalence rates by age subgroups. Thus, age may have been a source of the heterogeneity in our study. Future studies of patients with TJA are encouraged to report age-specific prevalence rates. As many patients over 65 years of age undergo TJA, it would be an interesting study to explore the effect of preoperative anemia on the postoperative period of arthroplasty in this or older age group [63].

To our knowledge, this is the first meta-analysis to assess the impact of preoperative anemia on TJA outcomes. The strength of this study is that it provides evidence from an evidence-based medical perspective to reinforce surgeons' caution in approaching preoperative anemia after it has been fully demonstrated that preoperative anemia has several detrimental effects on waiting for arthroplasty. Furthermore, our literature search was comprehensive, enabling us to make meaningful estimates of the impact of the clinically significant outcomes. However, this study has several limitations. First, this study included only 21 retrospective, single-center, or multicenter studies, some of which were small-sample studies, and it suffers from the standard bias of this type of study. Second, the period of the study was either long or short, and some important practical changes may have occurred during this period. These changes may have led to the biases associated with the assessment. Third, the overall heterogeneity of the studies was high, which may be due to differences in sample size, study population, mean age, sex differences, and experimental methods of individual studies. Therefore, this study may have had an assessment-related bias.

## Summary

Preoperative anemia is common in patients awaiting THR or TKR. The prevalence of preoperative anemia is 22% and is associated with poorer postoperative outcomes and increased transfusion volumes and rates. This study confirms that anemia is an independent factor associated with poor outcomes after primary or revision arthroplasty. Therefore, surgeons should strongly consider preoperative, timely, and optimal anemia, as it may reduce the "anemia-related negative outcomes" after arthroplasty.

## **Supplementary Information**

The online version contains supplementary material available at https://doi. org/10.1186/s13018-024-04706-y.

Additional file 1. Annex 1 Search formulate.

Additional file 2. Annex 2 Literature screening flow chart.

Additional file 3. Annex 3 Kappa.

Additional file 4. Annex 4 Sensitivity analysis and Egger.

## Author contributions

Hong-Zhang Guo, Yong-Ze Yang and Fu-Qiang Zhang; Data curation: Yong-Ze Yang, Guo-Rong Ma; Formal analysis: An-Reng Zhang, Peng-Fei Li; Funding acquisition: Hong-Zhang Guo; Investigation: Yong-Ze Yang, Guo-Rong Ma, Hong-Zhang Guo; Methodology: Hui Zhang; Software: Yong-Ze Yang; Supervision: Yong-Ze Yang; Validation: Guo-Rong Ma.; Visualization: Yong-Ze Yang; Writing—original draft: Fu-Qiang Zhang and Yong-Ze Yang; Writing—review & editing: Hong-Zhang Guo.

## Funding

This study is supported by the Natural Science Foundation of Gansu Province, China. (20JR10RA358). The project number (GSWSKY-2019-68) and name (Gansu Province Health Sector Project).

## Declarations

# Consent for publication

## Not applicable.

### Competing interests

The authors declare that they have no competing interests.

<sup>1</sup>First Clinical Medical College of Gansu, University of Traditional Chinese Medicine, Lanzhou, China. <sup>2</sup>People's Hospital of Gansu Province, Chengguan District, 204 Donggang West Road, Lanzhou 730000, China.

Received: 4 October 2023 Accepted: 29 March 2024 Published: 18 April 2024

#### References

- Jans Ø, Jørgensen C, Kehlet H, Johansson PI. Role of preoperative anemia for risk of transfusion and postoperative morbidity in fast-track hip and knee arthroplasty. Transfusion. 2014;54(3):717–26.
- Serrano-Trenas JA, Ugalde PF, Cabello LM, Chofles LC, Lázaro PS, Benítez PC. Role of perioperative intravenous iron therapy in elderly hip fracture patients: a single-center randomized controlled trial. Transfusion. 2011;51(1):97–104.
- Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing the requirement for allogeneic blood transfusion: a systematic review and meta-analysis of randomized clinical trials. BMJ. 2013;347: f4822.
- Spahn DR. Anemia and patient blood management in hip and knee surgery: a systematic review of the literature. Anesthesiology. 2010;113(2):482–95.
- Beattie WS, Karkouti K, Wijeysundera DN, Tait G. Risk associated with preoperative anemia in noncardiac surgery: a single-center cohort study. Anesthesiology. 2009;110(3):574–81.
- Rosencher N, Kerkkamp HE, Macheras G, Munuera LM, Menichella G, Barton DM, et al. Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe. Transfusion. 2003;43(4):459–69.
- Abdullah HR, Sim YE, Hao Y, Lin GY, Liew GHC, Lamoureux EL, et al. Association between preoperative anemiaanemia with a length of hospital stay among patients undergoing primary total knee arthroplasty in Singapore: a single-centre retrospective study. BMJ Open. 2017;7(6): e016403.
- Husted H, Holm G, Jacobsen S. Predictors of length of stay and patient satisfaction after hip and knee replacement surgery: fast-track experience in 712 patients. Acta Orthop. 2008;79(2):168–73.
- Boralessa H, Goldhill DR, Tucker K, Mortimer AJ, Grant-Casey J. National comparative audit of blood use in elective primary unilateral total hip replacement surgery in the UK. Ann R Coll Surg Engl. 2009;91(7):599–605
- Williamson LM, Lowe S, Love EM, Cohen H, Soldan K, McClelland DB, et al. Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports. BMJ. 1999;319(7201):16–9.
- Hill GE, Frawley WH, Griffith KE, Forestner JE, Minei JP. Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a metaanalysis. J Trauma. 2003;54(5):908–14.
- 12. Weber EWG, Slappendel R, Prins MH, van der Schaaf DB, Durieux ME, Strümper D. Perioperative blood transfusions and delayed wound healing after hip replacement surgery: effects on duration of hospitalization. Anesth Analg. 2005;100(5):1416–21.
- Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Jt Surg Am. 2007;89(4):780–5.
- Lu M, Sing DC, Kuo AC, Hansen EN. Preoperative anemia independently predicts 30-day complications after aseptic and septic revision total joint arthroplasty. J Arthroplasty. 2017;32(9s):S197-s201.
- Neuwirth AL, Boddapati V, Held MB, Grosso MJ, Shah RP, Geller JA, et al. Preoperative anemia is associated with 30-day morbidity in total knee arthroplasty. Orthopedics. 2022;45(2):e86–90.
- Karas V, Kildow BJ, Baumgartner BT, Green CL, Attarian DE, Bolognesi MP, et al. Preoperative patient profile in total hip and knee arthroplasty: predictive of increased medicare payments in a bundled payment model. J Arthroplasty. 2018;33(9):2728-33.e3.
- Gu A, Malahias MA, Selemon NA, Wei C, Gerhard EF, Cohen JS, et al. Increased severity of anaemia is associated with 30-day complications following total joint replacement. Bone Jt J. 2020;102-b(4):485–94.

- Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358: j4008.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.
- Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and nonrandomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–84.
- Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64(4):380–2.
- Bhandari M, Bajammal S, Guyatt GH, Griffith L, Busse JW, Schünemann H, et al. Effect of bisphosphonates on periprosthetic bone mineral density after total joint arthroplasty. A meta-analysis. J Bone Jt Surg Am. 2005;87(2):293–301.
- Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–80.
- 24. Kasivisvanathan R, Ramesh V, Rao Baikady R, Nadaraja S. Preoperative anaemia is associated with increased allogeneic pack red cell transfusion in revision hip and knee joint arthroplasty: a retrospective analysis of 5387 patients over a 10-year period at a single high volume centre. Transfus Med. 2016;26(4):271–7.
- Myers E, O'Grady P, Dolan AM. The influence of preclinical anaemia on outcome following total hip replacement. Arch Orthop Trauma Surg. 2004;124(10):699–701.
- Rogers BA, Cowie A, Alcock C, Rosson JW. Identification and treatment of anaemia in patients awaiting hip replacement. Ann R Coll Surg Engl. 2008;90(6):504–7.
- Saleh E, McClelland DB, Hay A, Semple D, Walsh TS. Prevalence of anaemia before major joint arthroplasty and the potential impact of preoperative investigation and correction on perioperative blood transfusions. Br J Anaesth. 2007;99(6):801–8.
- Sandean D, Chatterji U, Qureshi H, Power R, Samaras M. Immediate haemoglobin testing in association with a dedicated anaemia clinic: effectiveness for primary total knee replacement patients. J Perioper Pract. 2022;32(12):332–7.
- Sandean D, Samaras M, Chatterji U, Power R, Qureshi H. Reducing blood transfusions in primary total hip replacement patients: effectiveness of near-patient testing and a dedicated preoperative anemia clinic. Rev Bras Ortop (Sao Paulo). 2022;57(4):569–76.
- Xiong X, Li T, Cheng B. Anemia and formation of deep vein thrombosis before operation in patients with knee osteoarthritis: a cross-sectional study. J Orthop Surg Res. 2023;18(1):33.
- Greenky M, Gandhi K, Pulido L, Restrepo C, Parvizi J. Preoperative anemia in total joint arthroplasty: ls it associated with periprosthetic joint infection? Clin Orthop Relat Res. 2012;470(10):2695–701.
- Viola J, Gomez MM, Restrepo C, Maltenfort MG, Parvizi J. Preoperative anemia increases postoperative complications and mortality following total joint arthroplasty. J Arthroplasty. 2015;30(5):846–8.
- 33. Abdullah HR, Ranjakunalan N, Yeo W, Tan MH, Poopalalingam R, Sim YE. Association between preoperative anaemia and blood transfusion with long-term functional and quality of life outcomes amongst patients undergoing primary total knee arthroplasty in Singapore: a single-centre retrospective study. Qual Life Res. 2019;28(1):85–98.
- Lasocki S, Krauspe R, von Heymann C, Mezzacasa A, Chainey S, Spahn DR. PREPARE: the prevalence of perioperative anaemia and need for patient blood management in elective orthopaedic surgery: a multicentre, observational study. Eur J Anaesthesiol. 2015;32(3):160–7.
- Evans S, O'Loughlin E, Bruce J. Retrospective audit of blood transfusion and comparison with haemoglobin concentration in patients undergoing elective primary and revision lower limb arthroplasty. Anaesth Intensive Care. 2011;39(3):480–5.
- Meybohm P, Kohlhof H, Wirtz DC, Marzi I, Füllenbach C, Choorapoikayil S, et al. Preoperative anaemia in primary hip and knee arthroplasty. Z Orthop Unfall. 2020;158(2):194–200.

- Schatz C, Plötz W, Beckmann J, Bredow K, Leidl R, Buschner P. Associations of preoperative anemia and postoperative hemoglobin values with hospital costs in total knee arthroplasty (TKA). Arch Orthop Trauma Surg. 2023;143:1–11.
- Bailey A, Eisen I, Palmer A, Beaulé PE, Fergusson DA, Grammatopoulos G. Preoperative anemia in primary arthroplasty patients-prevalence, influence on outcome, and the effect of treatment. J Arthroplasty. 2021;36(7):2281–9.
- 39. Duarte GC, Catanoce AP, Zabeu JL, Ribeiro GN, Moschen M, de Oliveira NAG, et al. Association of preoperative anemia and increased risk of blood transfusion and length of hospital stay in adults undergoing hip and knee arthroplasty: an observational study in a single tertiary center. Health Sci Rep. 2021;4(4): e448.
- Wan S, Sparring V, Cabrales DA, Jansson K, Wikman A. Clinical and budget impact of treating preoperative anemia in major orthopedic surgery-a retrospective observational study. J Arthroplasty. 2020;35(11):3084–8.
- Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Jt Surg Am. 1999;81(1):2–10.
- Dunne JR, Malone D, Tracy JK, Gannon C, Napolitano LM. Perioperative anemia: an independent risk factor for infection, mortality, and resource utilization in surgery. J Surg Res. 2002;102(2):237–44.
- Gruson KI, Aharonoff GB, Egol KA, Zuckerman JD, Koval KJ. The relationship between admission hemoglobin level and outcome after hip fracture. J Orthop Trauma. 2002;16(1):39–44.
- 44. Hagino T, Ochiai S, Sato E, Maekawa S, Wako M, Haro H. The relationship between anemia at admission and outcome in patients older than 60 years with hip fracture. J Orthop Traumatol. 2009;10(3):119–22.
- Prochaska MT, Huisingh-Scheetz M, Meltzer D. Sex differences in fatigue and symptoms of anemia in relation to hemoglobin level in hospitalized patients. Ann Hematol. 2022;101(8):1873–5.
- Kanias T, Busch MP. Diversity in a blood bag: application of omics technologies to inform precision transfusion medicine. Blood Transfus. 2019;17(4):258–62.
- Schwartzberg LS, Fortner BV, Houts AC. Sex differences in patients who have cancer with mild anemia: symptom burden and quality of life. Support Cancer Ther. 2005;2(4):241–6.
- Kirkland KB, Briggs JP, Trivette SL, Wilkinson WE, Sexton DJ. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol. 1999;20(11):725–30.
- Kurtz SM, Lau E, Schmier J, Ong KL, Zhao K, Parvizi J. Infection burden for hip and knee arthroplasty in the United States. J Arthroplasty. 2008;23(7):984–91.
- Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood. 2009;113(15):3406–17.
- Seicean A, Alan N, Seicean S, Neuhauser D, Weil RJ. The effect of blood transfusion on short-term, perioperative outcomes in elective spine surgery. J Clin Neurosci. 2014;21(9):1579–85.
- Potaczek DP, Jankowska EA, Wypasek E, Undas A. Iron deficiency: a novel risk factor of recurrence in patients after unprovoked venous thromboembolism. Pol Arch Med Wewn. 2016;126(3):159–65.
- Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e278S-e325S.
- Bala A, Huddleston JI 3rd, Goodman SB, Maloney WJ, Amanatullah DF. Venous thromboembolism prophylaxis after TKA: Aspirin, warfarin, enoxaparin, or factor Xa inhibitors? Clin Orthop Relat Res. 2017;475(9):2205–13.
- Barshtein G, Ben-Ami R, Yedgar S. Role of red blood cell flow behavior in hemodynamics and hemostasis. Expert Rev Cardiovasc Ther. 2007;5(4):743–52.
- Meizoso JP, Karcutskie CA, Ray JJ, Ruiz X, Ginzburg E, Namias N, et al. A simplified stratification system for venous thromboembolism risk in severely injured trauma patients. J Surg Res. 2017;207:138–44.
- Wang P, Kandemir U, Zhang B, Wang B, Li J, Zhuang Y, et al. Incidence and risk factors of deep vein thrombosis in patients with pelvic and acetabular fractures. Clin Appl Thromb Hemost. 2019;25:1076029619845066.

- Zhang H, Wu L, Cheng B. Preoperative anemia and deep vein thrombosis in patients with perioperative bone trauma: a cohort study. BMC Musculoskelet Disord. 2022;23(1):905.
- Froessler B, Palm P, Weber I, Hodyl NA, Singh R, Murphy EM. The important role for intravenous iron in perioperative patient blood management in major abdominal surgery: a randomized controlled trial. Ann Surg. 2016;264(1):41–6.
- 60. YYYY.
- Beyer I, Compté N, Busuioc A, Cappelle S, Lanoy C, Cytryn E. Anemia and transfusions in geriatric patients: a time for evaluation. Hematology. 2010;15(2):116–21.
- Safiri S, Kolahi AA, Noori M, Nejadghaderi SA, Karamzad N, Bragazzi NL, et al. Burden of anemia and its underlying causes in 204 countries and territories, 1990–2019: results from the Global Burden of Disease Study 2019. J Hematol Oncol. 2021;14(1):185.
- 63. Marton I, Agócs S, Babik B. Epidemiology of anemia. Orv Hetil. 2020;161(37):1569–73.

## **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.